url	label_history	PharmGKB ID	Name	Source	Biomarker Flag	Testing Level	Has Prescribing Info	Has Dosing Info	Has Alternate Drug	Has Other Prescribing Guidance	Cancer Genome	Prescribing	Chemicals	Genes	Variants/Haplotypes	Latest History Date (YYYY-MM-DD)
https://www.pharmgkb.org/labelAnnotation/PA166269401		PA166269401	Annotation of EMA Label for nateglinide and CYP2C9	EMA									nateglinide	CYP2C9		11/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166269701		PA166269701	"Annotation of EMA Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC"	EMA		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166273281		PA166273281	Annotation of EMA Label for nusinersen and SMN2	EMA									nusinersen	SMN2		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166273261		PA166273261	Annotation of EMA Label for ospemifene and CYP2C9	EMA									ospemifene	CYP2C9		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166271261		PA166271261	Annotation of EMA Label for tegafur / gimeracil / oteracil and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	tegafur / gimeracil / oteracil	DPYD	"DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T"	
https://www.pharmgkb.org/labelAnnotation/PA166273521		PA166273521	"Annotation of EMA Label for ipilimumab and ALK, CD274, EGFR"	EMA		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166273423		PA166273423	"Annotation of EMA Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5"	EMA		Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166273501		PA166273501	"Annotation of EMA Label for ipilimumab and CTLA4, HLA-A"	EMA		No Clinical PGx							ipilimumab	CTLA4; HLA-A	HLA-A*02:01	8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166272241		PA166272241	Annotation of HCSC Label for upadacitinib and CYP2D6	HCSC		No Clinical PGx							upadacitinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166272321		PA166272321	"Annotation of HCSC Label for tipiracil / trifluridine and ERBB2, KRAS"	HCSC							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166271361		PA166271361	Annotation of HCSC Label for capmatinib and MET	HCSC		Testing Required					Cancer Genome		capmatinib	MET		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166272581		PA166272581	Annotation of HCSC Label for sotorasib and KRAS	HCSC		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166272601		PA166272601	Annotation of EMA Label for sotorasib and KRAS	EMA		Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166271481		PA166271481	Annotation of HCSC Label for escitalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166184114		PA166184114	Annotation of Swissmedic Label for capecitabine and DPYD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	capecitabine	DPYD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184117		PA166184117	Annotation of Swissmedic Label for carbasalate calcium and G6PD	Swissmedic		Actionable PGx							carbasalate calcium	G6PD		9/30/2022
https://www.pharmgkb.org/labelAnnotation/PA166184126		PA166184126	Annotation of Swissmedic Label for codeine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184405		PA166184405	Annotation of Swissmedic Label for brexpiprazole and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184116		PA166184116	Annotation of Swissmedic Label for carbamazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166272701		PA166272701	Annotation of EMA Label for rimegepant and CYP2C9	EMA		No Clinical PGx							rimegepant	CYP2C9		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166272721		PA166272721	"Annotation of EMA Label for risdiplam and SMN1, SMN2"	EMA		Testing Required							risdiplam	SMN1; SMN2		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166271541		PA166271541	Annotation of EMA Label for sacituzumab govitecan and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166273981		PA166273981	"Annotation of HCSC Label for asciminib and ABL1, BCR"	HCSC		Testing Required					Cancer Genome		asciminib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166184506		PA166184506	Annotation of Swissmedic Label for dolutegravir / abacavir / lamivudine and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	dolutegravir / abacavir / lamivudine	HLA-B	HLA-B*57:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184122		PA166184122	Annotation of Swissmedic Label for ciprofloxacin and G6PD	Swissmedic		Actionable PGx							ciprofloxacin	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184124		PA166184124	Annotation of Swissmedic Label for clomipramine and CYP2D6	Swissmedic		Actionable PGx							clomipramine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184133		PA166184133	Annotation of Swissmedic Label for dexlansoprazole and CYP2C19	Swissmedic		Actionable PGx							dexlansoprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166184134		PA166184134	Annotation of Swissmedic Label for dextromethorphan and CYP2D6	Swissmedic		Actionable PGx							dextromethorphan	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184442		PA166184442	Annotation of Swissmedic Label for duloxetine and CYP2D6	Swissmedic		Actionable PGx							duloxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184449		PA166184449	Annotation of Swissmedic Label for flucytosine and DPYD	Swissmedic		Testing Recommended							flucytosine	DPYD		
https://www.pharmgkb.org/labelAnnotation/PA166183786		PA166183786	"Annotation of Swissmedic Label for amlodipine / atorvastatin / perindopril arginine and G6PD, SLCO1B1"	Swissmedic		Actionable PGx							amlodipine / atorvastatin / perindopril arginine	G6PD; SLCO1B1	rs4149056	
https://www.pharmgkb.org/labelAnnotation/PA166271561		PA166271561	Annotation of HCSC Label for sacituzumab govitecan and UGT1A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166274002		PA166274002	"Annotation of HCSC Label for blinatumomab and ABL1, BCR, CD19"	HCSC							Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166272781		PA166272781	Annotation of EMA Label for selpercatinib and RET	EMA		Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166272801		PA166272801	"Annotation of EMA Label for setmelanotide and LEPR, PCSK1, POMC"	EMA		Testing Required							setmelanotide	LEPR; PCSK1; POMC		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166272821		PA166272821	Annotation of EMA Label for siponimod and CYP2C9	EMA		Testing Required	Prescribing Info	Dosing Info				Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*11; CYP2C9*2; CYP2C9*3; CYP2C9*5; CYP2C9*6; CYP2C9*8	
https://www.pharmgkb.org/labelAnnotation/PA166272841		PA166272841	Annotation of EMA Label for sodium oxybate and ALDH5A1	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166273101		PA166273101	Annotation of EMA Label for pitolisant and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166278442		PA166278442	"Annotation of HCSC Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1"	HCSC		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166278601		PA166278601	Annotation of HCSC Label for selpercatinib and RET	HCSC		Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166184157		PA166184157	Annotation of Swissmedic Label for ofloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ofloxacin	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184173		PA166184173	Annotation of Swissmedic Label for oxcarbazepine and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184120		PA166184120	Annotation of Swissmedic Label for quinine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184403		PA166184403	Annotation of Swissmedic Label for rasburicase and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184450		PA166184450	Annotation of Swissmedic Label for fluorouracil and DPYD	Swissmedic		Testing Required							fluorouracil	DPYD		
https://www.pharmgkb.org/labelAnnotation/PA166184452		PA166184452	Annotation of Swissmedic Label for fluoxetine and CYP2D6	Swissmedic		Informative PGx							fluoxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184461		PA166184461	Annotation of Swissmedic Label for hydroxychloroquine and G6PD	Swissmedic		Actionable PGx							hydroxychloroquine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166183900		PA166183900	Annotation of Swissmedic Label for moclobemide and CYP2C19	Swissmedic		Actionable PGx							moclobemide	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166183910		PA166183910	Annotation of Swissmedic Label for nebivolol and CYP2D6	Swissmedic		Informative PGx							nebivolol	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184221		PA166184221	Annotation of Swissmedic Label for palonosetron and CYP2D6	Swissmedic		Informative PGx							palonosetron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184268		PA166184268	Annotation of Swissmedic Label for pazopanib and HLA-B	Swissmedic		Actionable PGx							pazopanib	HLA-B	HLA-B*15:02	
https://www.pharmgkb.org/labelAnnotation/PA166184395		PA166184395	Annotation of Swissmedic Label for propafenone and CYP2D6	Swissmedic		Actionable PGx							propafenone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184388		PA166184388	"Annotation of Swissmedic Label for losartan and CYP2C9, CYP3A4"	Swissmedic		Actionable PGx							losartan	CYP2C9; CYP3A4		
https://www.pharmgkb.org/labelAnnotation/PA166184390		PA166184390	Annotation of Swissmedic Label for sulfamethoxazole / trimethoprim and G6PD	Swissmedic		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166281081		PA166281081	"Annotation of EMA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	EMA									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166129526		PA166129526	Annotation of HCSC Label for ceritinib and ALK	HCSC		Testing Required					Cancer Genome		ceritinib	ALK		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166129527		PA166129527	"Annotation of HCSC Label for ponatinib and ABI1, BCR"	HCSC		Testing Required					Cancer Genome		ponatinib	ABI1; BCR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166129525		PA166129525	Annotation of HCSC Label for carglumic acid and NAGS	HCSC									carglumic acid	NAGS		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166281722		PA166281722	Annotation of HCSC Label for pralsetinib and RET	HCSC		Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166281761		PA166281761	Annotation of HCSC Label for paliperidone and CYP2D6	HCSC		No Clinical PGx							paliperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166283201		PA166283201	Annotation of HCSC Label for mivacurium and BCHE	HCSC		Actionable PGx							mivacurium	BCHE		
https://www.pharmgkb.org/labelAnnotation/PA166283221		PA166283221	Annotation of HCSC Label for lumasiran and AGXT	HCSC									lumasiran	AGXT		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166284541		PA166284541	"Annotation of EMA Label for encorafenib and HRAS, KRAS, NRAS"	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166283241		PA166283241	Annotation of HCSC Label for lenvatinib	HCSC		Testing Required					Cancer Genome		lenvatinib			4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166284681		PA166284681	Annotation of EMA Label for pembrolizumab and BRAF	EMA							Cancer Genome		pembrolizumab	BRAF	rs113488022	11/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166283161		PA166283161	"Annotation of HCSC Label for niraparib and BRCA1, BRCA2"	HCSC		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166284761		PA166284761	Annotation of HCSC Label for cabotegravir / rilpivirine and UGT1A1	HCSC		No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166284241		PA166284241	Annotation of HCSC Label for fosphenytoin and HLA-B	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	fosphenytoin	HLA-B	HLA-B*15:02	8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166224081		PA166224081	Annotation of HCSC Label for oxcarbazepine and HLA-A	HCSC		Informative PGx							oxcarbazepine	HLA-A	HLA-A*31:01	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166283802		PA166283802	"Annotation of HCSC Label for givosiran and CPOX, HMBS, PPOX"	HCSC									givosiran	CPOX; HMBS; PPOX		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166284561		PA166284561	"Annotation of HCSC Label for encorafenib and HRAS, KRAS, NRAS"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166272361		PA166272361	Annotation of HCSC Label for tafamidis and TTR	HCSC									tafamidis	TTR		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166278561		PA166278561	Annotation of HCSC Label for sodium oxybate and ALDH5A1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		7/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166283821		PA166283821	"Annotation of HCSC Label for ipilimumab and ALK, CD274, EGFR"	HCSC		Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166284721		PA166284721	"Annotation of HCSC Label for nivolumab and ALK, CD274, EGFR, ERBB2"	HCSC		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166272341		PA166272341	Annotation of HCSC Label for tepotinib and MET	HCSC		Testing Required					Cancer Genome		tepotinib	MET		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166281741		PA166281741	Annotation of HCSC Label for pitolisant and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166273302		PA166273302	Annotation of EMA Label for nivolumab and BRAF	EMA							Cancer Genome		nivolumab	BRAF	rs113488022	8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166283961		PA166283961	Annotation of EMA Label for fosdenopterin and MOCS1	EMA		Testing Required							fosdenopterin	MOCS1		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166283941		PA166283941	Annotation of EMA Label for trastuzumab deruxtecan and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166273481		PA166273481	Annotation of EMA Label for isatuximab and CD38	EMA							Cancer Genome		isatuximab	CD38		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166283981		PA166283981	Annotation of EMA Label for evinacumab and LDLR	EMA									evinacumab	LDLR		8/20/2024
https://www.pharmgkb.org/labelAnnotation/PA166284001		PA166284001	Annotation of EMA Label for enfortumab vedotin and NECTIN4	EMA							Cancer Genome		enfortumab vedotin	NECTIN4		11/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166284021		PA166284021	Annotation of HCSC Label for enfortumab vedotin and NECTIN4	HCSC							Cancer Genome		enfortumab vedotin	NECTIN4		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166277761		PA166277761	Annotation of FDA Label for tebentafusp and HLA-A	FDA	On FDA Biomarker List	Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166229941		PA166229941	"Annotation of HCSC Label for atezolizumab and ALK, CD274, EGFR"	HCSC		Testing Required					Cancer Genome		atezolizumab	ALK; CD274; EGFR		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166284062		PA166284062	"Annotation of HCSC Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1"	HCSC		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166284081		PA166284081	"Annotation of HCSC Label for erdafitinib and FGFR2, FGFR3"	HCSC		Testing Required					Cancer Genome		erdafitinib	FGFR2; FGFR3		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166272641		PA166272641	Annotation of EMA Label for tepotinib and MET	EMA		Testing Required					Cancer Genome		tepotinib	MET		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166284101		PA166284101	Annotation of HCSC Label for erdafitinib and CYP2C9	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166278202		PA166278202	"Annotation of EMA Label for azacitidine and KRAS, NRAS, PTPN11"	EMA							Cancer Genome		azacitidine	KRAS; NRAS; PTPN11		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166284261		PA166284261	Annotation of HCSC Label for fosphenytoin and CYP2C9	HCSC		No Clinical PGx							fosphenytoin	CYP2C9		
https://www.pharmgkb.org/labelAnnotation/PA166229921		PA166229921	Annotation of HCSC Label for amifampridine and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2		
https://www.pharmgkb.org/labelAnnotation/PA166283901		PA166283901	"Annotation of HCSC Label for inclisiran and APOB, LDLR, PCSK9"	HCSC									inclisiran	APOB; LDLR; PCSK9		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166273462		PA166273462	Annotation of EMA Label for lenvatinib	EMA							Cancer Genome		lenvatinib			8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166184172		PA166184172	Annotation of Swissmedic Label for Opium derivatives and expectorants and CYP2D6	Swissmedic		Actionable PGx							Opium derivatives and expectorants	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184112		PA166184112	"Annotation of Swissmedic Label for azathioprine and NUDT15, TPMT"	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15; TPMT		
https://www.pharmgkb.org/labelAnnotation/PA166184125		PA166184125	Annotation of Swissmedic Label for clopidogrel and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clopidogrel	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	11/5/2019
https://www.pharmgkb.org/labelAnnotation/PA166183181		PA166183181	Annotation of EMA Label for lesinurad and CYP2C9	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3	8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166182948		PA166182948	Annotation of EMA Label for encorafenib and BRAF	EMA		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166182952		PA166182952	Annotation of EMA Label for irinotecan and UGT1A1	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	5/31/2024
https://www.pharmgkb.org/labelAnnotation/PA166184121		PA166184121	Annotation of Swissmedic Label for chloroquine and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	chloroquine	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184429		PA166184429	Annotation of Swissmedic Label for ezetimibe / simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	ezetimibe / simvastatin	SLCO1B1	rs4149056	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184502		PA166184502	Annotation of Swissmedic Label for lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	lamivudine / abacavir	HLA-B	HLA-B*57:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184113		PA166184113	Annotation of Swissmedic Label for bisoprolol fumarate / perindopril arginine and G6PD	Swissmedic		Actionable PGx							bisoprolol fumarate / perindopril arginine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184132		PA166184132	Annotation of Swissmedic Label for dasabuvir and IFNL3	Swissmedic		Actionable PGx							dasabuvir	IFNL3		
https://www.pharmgkb.org/labelAnnotation/PA166184443		PA166184443	Annotation of Swissmedic Label for efavirenz and CYP2B6	Swissmedic		Actionable PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274	
https://www.pharmgkb.org/labelAnnotation/PA166184446		PA166184446	Annotation of Swissmedic Label for escitalopram and CYP2D6	Swissmedic		Informative PGx							escitalopram	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184447		PA166184447	Annotation of Swissmedic Label for fesoterodine and CYP2D6	Swissmedic		Actionable PGx							fesoterodine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184451		PA166184451	Annotation of Swissmedic Label for fluorouracil and TYMS	Swissmedic		Actionable PGx							fluorouracil	TYMS	rs45445694	
https://www.pharmgkb.org/labelAnnotation/PA166184455		PA166184455	Annotation of Swissmedic Label for gefitinib and CYP2D6	Swissmedic		Actionable PGx							gefitinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184457		PA166184457	Annotation of Swissmedic Label for gliclazide and G6PD	Swissmedic		Actionable PGx							gliclazide	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184374		PA166184374	Annotation of Swissmedic Label for ibrutinib and CYP2D6	Swissmedic		Informative PGx							ibrutinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184383		PA166184383	"Annotation of Swissmedic Label for lapatinib and HLA-DQA1, HLA-DRB1"	Swissmedic		Actionable PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
https://www.pharmgkb.org/labelAnnotation/PA166184427		PA166184427	"Annotation of Swissmedic Label for ezetimibe / rosuvastatin and ABCG2, SLCO1B1"	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	ezetimibe / rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166184155		PA166184155	Annotation of Swissmedic Label for nitrofurantoin and G6PD	Swissmedic		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184500		PA166184500	Annotation of Swissmedic Label for simvastatin and SLCO1B1	Swissmedic		Testing Recommended	Prescribing Info					Prescribing	simvastatin	SLCO1B1	rs4149056	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184160		PA166184160	Annotation of Swissmedic Label for ondansetron and CYP2D6	Swissmedic		Informative PGx							ondansetron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184177		PA166184177	Annotation of Swissmedic Label for oxycodone and CYP2D6	Swissmedic		Actionable PGx							oxycodone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184220		PA166184220	Annotation of Swissmedic Label for paliperidone and CYP2D6	Swissmedic		Informative PGx							paliperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184286		PA166184286	Annotation of Swissmedic Label for perindopril and G6PD	Swissmedic		Actionable PGx							perindopril	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184393		PA166184393	Annotation of Swissmedic Label for pitavastatin and SLCO1B1	Swissmedic		Actionable PGx							pitavastatin	SLCO1B1		
https://www.pharmgkb.org/labelAnnotation/PA166184396		PA166184396	Annotation of Swissmedic Label for rabeprazole and CYP2C19	Swissmedic		Actionable PGx							rabeprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166184421		PA166184421	Annotation of Swissmedic Label for risperidone and CYP2D6	Swissmedic		Informative PGx							risperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184389		PA166184389	Annotation of Swissmedic Label for sulfadiazine and G6PD	Swissmedic		Actionable PGx							sulfadiazine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184392		PA166184392	Annotation of Swissmedic Label for tamoxifen and CYP2D6	Swissmedic		Actionable PGx							tamoxifen	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184391		PA166184391	Annotation of Swissmedic Label for sulfasalazine and G6PD	Swissmedic		Actionable PGx							sulfasalazine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184425		PA166184425	Annotation of Swissmedic Label for tolperisone and CYP2D6	Swissmedic		Actionable PGx							tolperisone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184236		PA166184236	Annotation of Swissmedic Label for umeclidinium / vilanterol and CYP2D6	Swissmedic		Informative PGx							umeclidinium / vilanterol	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184239		PA166184239	Annotation of Swissmedic Label for vortioxetine and CYP2D6	Swissmedic		Actionable PGx							vortioxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184386		PA166184386	"Annotation of Swissmedic Label for letermovir and SLCO1B1, UGT1A1"	Swissmedic		Informative PGx							letermovir	SLCO1B1; UGT1A1	rs2306283; rs4148323; rs4149032; rs4149056; UGT1A1*28	
https://www.pharmgkb.org/labelAnnotation/PA166122967		PA166122967	Annotation of EMA Label for fesoterodine and CYP2D6	EMA		Informative PGx							fesoterodine	CYP2D6		8/7/2014
https://www.pharmgkb.org/labelAnnotation/PA166119823		PA166119823	Annotation of EMA Label for afatinib and EGFR	EMA		Testing Required					Cancer Genome		afatinib	EGFR		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166286161		PA166286161	Annotation of HCSC Label for allopurinol and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	6/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166184422		PA166184422	Annotation of Swissmedic Label for tetrabenazine and CYP2D6	Swissmedic		Testing Required	Prescribing Info					Prescribing	tetrabenazine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127634		PA166127634	Annotation of HCSC Label for atorvastatin and LDLR	HCSC									atorvastatin	LDLR		9/26/2023
https://www.pharmgkb.org/labelAnnotation/PA166122487		PA166122487	Annotation of EMA Label for propranolol and CYP2D6	EMA		No Clinical PGx							propranolol	CYP2D6		6/26/2014
https://www.pharmgkb.org/labelAnnotation/PA166117941		PA166117941	"Annotation of EMA Label for bosutinib and ABL1, BCR"	EMA		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104844		PA166104844	Annotation of EMA Label for erlotinib and EGFR	EMA		Testing Required					Cancer Genome		erlotinib	EGFR		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104834		PA166104834	Annotation of FDA Label for lenalidomide	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenalidomide			5/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166104841		PA166104841	Annotation of EMA Label for clopidogrel and CYP2C19	EMA		Informative PGx							clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166127706		PA166127706	Annotation of HCSC Label for rabeprazole and CYP2C19	HCSC		Informative PGx							rabeprazole	CYP2C19		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166122547		PA166122547	Annotation of EMA Label for trastuzumab emtansine and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127702		PA166127702	"Annotation of HCSC Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYP2D6"	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4; CYP2D6		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127707		PA166127707	Annotation of HCSC Label for rasburicase and G6PD	HCSC		Testing Recommended							rasburicase	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166114481		PA166114481	Annotation of EMA Label for trastuzumab and ERBB2	EMA		Testing Required					Cancer Genome		trastuzumab	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127633		PA166127633	Annotation of HCSC Label for atomoxetine and CYP2D6	HCSC		Informative PGx							atomoxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104920		PA166104920	Annotation of FDA Label for trastuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab	ERBB2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104902		PA166104902	Annotation of FDA Label for sulfadiazine and G6PD	FDA	On FDA Biomarker List	Informative PGx							sulfadiazine	G6PD		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104881		PA166104881	Annotation of FDA Label for glyburide and G6PD	FDA	Formerly on FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166104793		PA166104793	Annotation of FDA Label for risperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							risperidone	CYP2D6		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166159707		PA166159707	Annotation of HCSC Label for atazanavir and CYP2C19	HCSC		Informative PGx							atazanavir	CYP2C19		5/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166182931		PA166182931	Annotation of EMA Label for brigatinib and ALK	EMA		Testing Required					Cancer Genome		brigatinib	ALK		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166115435		PA166115435	Annotation of EMA Label for timolol and CYP2D6	EMA									timolol	CYP2D6		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166114913		PA166114913	Annotation of FDA Label for dabrafenib and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	G6PD		5/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166114378		PA166114378	Annotation of EMA Label for telaprevir and IFNL3	EMA		Informative PGx							telaprevir	IFNL3		10/28/2013
https://www.pharmgkb.org/labelAnnotation/PA166122066		PA166122066	Annotation of EMA Label for pertuzumab and ERBB2	EMA		Testing Required					Cancer Genome		pertuzumab	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166122969		PA166122969	Annotation of EMA Label for vardenafil	EMA									vardenafil			8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166119826		PA166119826	Annotation of EMA Label for dabrafenib and BRAF	EMA		Testing Required					Cancer Genome		dabrafenib	BRAF		5/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166122826		PA166122826	"Annotation of EMA Label for voriconazole and CYP2C19, CYP2C9, CYP3A4"	EMA									voriconazole	CYP2C19; CYP2C9; CYP3A4		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166127701		PA166127701	Annotation of HCSC Label for phenytoin and HLA-B	HCSC		Testing Recommended							phenytoin	HLA-B		
https://www.pharmgkb.org/labelAnnotation/PA166127700		PA166127700	Annotation of HCSC Label for pertuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		pertuzumab	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127635		PA166127635	Annotation of HCSC Label for azathioprine and TPMT	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	azathioprine	TPMT		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166127647		PA166127647	Annotation of HCSC Label for celecoxib and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	celecoxib	CYP2C9	CYP2C9*3	7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166127650		PA166127650	Annotation of HCSC Label for citalopram and CYP2C19	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166127705		PA166127705	Annotation of HCSC Label for quinine and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	quinine	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166105321		PA166105321	"Annotation of EMA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5"	EMA		No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		10/27/2013
https://www.pharmgkb.org/labelAnnotation/PA166127704		PA166127704	Annotation of HCSC Label for propafenone and CYP2D6	HCSC		Informative PGx							propafenone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127646		PA166127646	Annotation of HCSC Label for carvedilol and CYP2D6	HCSC		Informative PGx							carvedilol	CYP2D6		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166104786		PA166104786	Annotation of FDA Label for chloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroquine	G6PD		9/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166104887		PA166104887	Annotation of FDA Label for iloperidone and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	iloperidone	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166127709		PA166127709	Annotation of HCSC Label for rosuvastatin and LDLR	HCSC									rosuvastatin	LDLR		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166127708		PA166127708	Annotation of HCSC Label for risperidone and CYP2D6	HCSC		No Clinical PGx							risperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104785		PA166104785	Annotation of FDA Label for erlotinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erlotinib	EGFR	rs121434568	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166114903		PA166114903	Annotation of FDA Label for afatinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	8/1/2024
https://www.pharmgkb.org/labelAnnotation/PA166104872		PA166104872	Annotation of EMA Label for boceprevir and IFNL3	EMA		No Clinical PGx							boceprevir	IFNL3		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166104835		PA166104835	Annotation of FDA Label for fluoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info					Prescribing	fluoxetine	CYP2D6		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166104884		PA166104884	Annotation of FDA Label for clobazam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clobazam	CYP2C19		4/23/2019
https://www.pharmgkb.org/labelAnnotation/PA166104880		PA166104880	Annotation of FDA Label for nefazodone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nefazodone	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166104791		PA166104791	"Annotation of FDA Label for lapatinib and ERBB2, ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2; PGR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104782		PA166104782	"Annotation of FDA Label for azathioprine and NUDT15, TPMT"	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	azathioprine	NUDT15; TPMT		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166104775		PA166104775	Annotation of FDA Label for atorvastatin and LDLR	FDA	Formerly on FDA Biomarker List								atorvastatin	LDLR		12/4/2023
https://www.pharmgkb.org/labelAnnotation/PA166104830		PA166104830	Annotation of FDA Label for tiotropium and CYP2D6	FDA	Formerly on FDA Biomarker List								tiotropium	CYP2D6		8/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166104794		PA166104794	"Annotation of FDA Label for sodium benzoate / sodium phenylacetate and ARG1, ASL, ASS1, CPS1, NAGS, OTC"	FDA	Formerly on FDA Biomarker List								sodium benzoate / sodium phenylacetate	ARG1; ASL; ASS1; CPS1; NAGS; OTC		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166122546		PA166122546	Annotation of EMA Label for rituximab and MS4A1	EMA							Cancer Genome		rituximab	MS4A1		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166104822		PA166104822	Annotation of FDA Label for terbinafine and CYP2D6	FDA	Formerly on FDA Biomarker List								terbinafine	CYP2D6		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166104779		PA166104779	Annotation of EMA Label for indacaterol and UGT1A1	EMA		No Clinical PGx							indacaterol	UGT1A1		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166104869		PA166104869	Annotation of FDA Label for galantamine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							galantamine	CYP2D6		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166104850		PA166104850	Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2	FDA	On FDA Biomarker List	Informative PGx							isoniazid / pyrazinamide / rifampin	NAT2		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166104896		PA166104896	Annotation of EMA Label for abacavir and HLA-B	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	10/15/2013
https://www.pharmgkb.org/labelAnnotation/PA166104891		PA166104891	Annotation of FDA Label for nalidixic acid and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nalidixic acid	G6PD		12/18/2013
https://www.pharmgkb.org/labelAnnotation/PA166104825		PA166104825	Annotation of FDA Label for valproic acid and OTC	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC		2/16/2023
https://www.pharmgkb.org/labelAnnotation/PA166104805		PA166104805	Annotation of FDA Label for thioridazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	thioridazine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104862		PA166104862	Annotation of FDA Label for desipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							desipramine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104928		PA166104928	Annotation of EMA Label for ivacaftor and CFTR	EMA		Testing Required							ivacaftor	CFTR	rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs74503330; rs75527207; rs78655421; rs80282562	4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166104889		PA166104889	Annotation of FDA Label for pertuzumab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pertuzumab	ERBB2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104916		PA166104916	Annotation of FDA Label for codeine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6		9/18/2020
https://www.pharmgkb.org/labelAnnotation/PA166104814		PA166104814	Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19	FDA	On FDA Biomarker List								drospirenone / ethinyl estradiol	CYP2C19		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166104853		PA166104853	Annotation of FDA Label for cisplatin and TPMT	FDA	On FDA Biomarker List	Informative PGx							cisplatin	TPMT		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104905		PA166104905	Annotation of EMA Label for capecitabine and DPYD	EMA		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	"DPYD c.1129-5923C>G, c.1236G>A (HapB3); DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T"	6/3/2022
https://www.pharmgkb.org/labelAnnotation/PA166104922		PA166104922	Annotation of FDA Label for flurbiprofen and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	flurbiprofen	CYP2C9		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104870		PA166104870	Annotation of FDA Label for pimozide and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	pimozide	CYP2D6		8/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166104883		PA166104883	Annotation of FDA Label for denileukin diftitox and IL2RA	FDA	On FDA Biomarker List						Cancer Genome		denileukin diftitox	IL2RA		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166104876		PA166104876	Annotation of FDA Label for primaquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD		11/9/2017
https://www.pharmgkb.org/labelAnnotation/PA166114908		PA166114908	Annotation of FDA Label for carglumic acid and NAGS	FDA	On FDA Biomarker List								carglumic acid	NAGS		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166104898		PA166104898	Annotation of FDA Label for lansoprazole and CYP2C19	FDA	On FDA Biomarker List								lansoprazole	CYP2C19		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166104899		PA166104899	Annotation of EMA Label for aripiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	aripiprazole	CYP2D6		12/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166104904		PA166104904	Annotation of EMA Label for brentuximab vedotin and TNFRSF8	EMA							Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166123048		PA166123048	Annotation of EMA Label for cabazitaxel and CYP3A4	EMA									cabazitaxel	CYP3A4		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166104832		PA166104832	Annotation of FDA Label for carisoprodol and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carisoprodol	CYP2C19		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104843		PA166104843	Annotation of FDA Label for celecoxib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	celecoxib	CYP2C9	CYP2C9*3	2/5/2021
https://www.pharmgkb.org/labelAnnotation/PA166104908		PA166104908	"Annotation of EMA Label for cetuximab and EGFR, KRAS, NRAS"	EMA		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS; NRAS		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104930		PA166104930	Annotation of EMA Label for gefitinib and EGFR	EMA		Testing Required					Cancer Genome		gefitinib	EGFR		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104890		PA166104890	Annotation of FDA Label for ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor	CFTR	rs113993958; rs115545701; rs11971167; rs121908752; rs121908753; rs121908755; rs121908757; rs121909013; rs121909020; rs121909041; rs141033578; rs150212784; rs186045772; rs193922525; rs200321110; rs202179988; rs267606723; rs368505753; rs397508256; rs397508288; rs397508387; rs397508442; rs397508513; rs397508537; rs397508761; rs74503330; rs74551128; rs75039782; rs75527207; rs75541969; rs76151804; rs77834169; rs77932196; rs78655421; rs78769542; rs80224560; rs80282562	4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166104927		PA166104927	Annotation of EMA Label for lenalidomide	EMA		Testing Required					Cancer Genome		lenalidomide			5/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166104894		PA166104894	Annotation of EMA Label for rasburicase and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		2/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166119824		PA166119824	Annotation of EMA Label for belimumab and TNFSF13B	EMA									belimumab	TNFSF13B		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166122488		PA166122488	Annotation of EMA Label for regorafenib and KRAS	EMA		Informative PGx					Cancer Genome		regorafenib	KRAS		7/5/2022
https://www.pharmgkb.org/labelAnnotation/PA166114382		PA166114382	Annotation of EMA Label for ticagrelor and CYP2C19	EMA		Informative PGx							ticagrelor	CYP2C19		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166105240		PA166105240	Annotation of FDA Label for rituximab and MS4A1	FDA	On FDA Biomarker List						Cancer Genome		rituximab	MS4A1		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166119825		PA166119825	Annotation of EMA Label for carglumic acid and NAGS	EMA									carglumic acid	NAGS		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166121246		PA166121246	Annotation of EMA Label for ibritumomab and MS4A1	EMA							Cancer Genome		ibritumomab	MS4A1		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166121251		PA166121251	"Annotation of EMA Label for mercaptopurine and NUDT15, TPMT"	EMA		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232	7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166151881		PA166151881	Annotation of FDA Label for rasburicase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	rasburicase	G6PD		3/21/2016
https://www.pharmgkb.org/labelAnnotation/PA166159064		PA166159064	Annotation of FDA Label for elosulfase alfa and GALNS	FDA	On FDA Biomarker List	Testing Required							elosulfase alfa	GALNS		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166185194		PA166185194	"Annotation of FDA Label for raloxifene and ESR1, ESR2"	FDA	On FDA Biomarker List						Cancer Genome		raloxifene	ESR1; ESR2		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166159938		PA166159938	Annotation of HCSC Label for belimumab and TNFSF13B	HCSC									belimumab	TNFSF13B		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166160288		PA166160288	Annotation of HCSC Label for brentuximab vedotin and TNFRSF8	HCSC							Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166160289		PA166160289	Annotation of HCSC Label for brivaracetam and CYP2C19	HCSC		Informative PGx							brivaracetam	CYP2C19		7/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166183246		PA166183246	Annotation of EMA Label for osimertinib and EGFR	EMA		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	8/12/2024
https://www.pharmgkb.org/labelAnnotation/PA166182744		PA166182744	Annotation of FDA Label for lorlatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lorlatinib	ALK		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166182727		PA166182727	Annotation of FDA Label for ivosidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ivosidenib	IDH1		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166182940		PA166182940	"Annotation of EMA Label for cholic acid and AKR1D1, HSD3B7"	EMA									cholic acid	AKR1D1; HSD3B7		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166182726		PA166182726	Annotation of FDA Label for rivaroxaban and F5	FDA	On FDA Biomarker List								rivaroxaban	F5		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166160121		PA166160121	"Annotation of FDA Label for nivolumab and BRAF, ERBB2"	FDA	On FDA Biomarker List						Cancer Genome		nivolumab	BRAF; ERBB2	rs113488022	12/4/2023
https://www.pharmgkb.org/labelAnnotation/PA166182725		PA166182725	"Annotation of FDA Label for eribulin and ERBB2, ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		eribulin	ERBB2; ESR1; ESR2; PGR		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166182750		PA166182750	"Annotation of FDA Label for toremifene and ESR1, ESR2"	FDA	On FDA Biomarker List						Cancer Genome		toremifene	ESR1; ESR2		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166182787		PA166182787	Annotation of FDA Label for tolbutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolbutamide	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166182941		PA166182941	Annotation of EMA Label for cobimetinib and BRAF	EMA		Testing Required					Cancer Genome		cobimetinib	BRAF		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166182944		PA166182944	Annotation of EMA Label for duloxetine and CYP2D6	EMA		Informative PGx							duloxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166182943		PA166182943	Annotation of EMA Label for dolutegravir and UGT1A1	EMA		Informative PGx							dolutegravir	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166129528		PA166129528	Annotation of HCSC Label for sodium nitrite and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	G6PD		7/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183621		PA166183621	Annotation of Swissmedic Label for mefloquine and G6PD	Swissmedic		Informative PGx							mefloquine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166183593		PA166183593	Annotation of Swissmedic Label for acenocoumarol and CYP2C9	Swissmedic		Actionable PGx							acenocoumarol	CYP2C9	CYP2C9*2; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166182752		PA166182752	Annotation of FDA Label for talazoparib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		talazoparib	ERBB2		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166160051		PA166160051	Annotation of FDA Label for alectinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alectinib	ALK		8/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166184238		PA166184238	Annotation of Swissmedic Label for voriconazole and CYP2C19	Swissmedic		Actionable PGx							voriconazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166184404		PA166184404	"Annotation of Swissmedic Label for tamsulosin and CYP2D6, CYP3A4"	Swissmedic		Actionable PGx							tamsulosin	CYP2D6; CYP3A4		
https://www.pharmgkb.org/labelAnnotation/PA166151974		PA166151974	Annotation of HCSC Label for nilotinib and UGT1A1	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	nilotinib	UGT1A1		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166160010		PA166160010	Annotation of FDA Label for dolutegravir and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							dolutegravir	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166183590		PA166183590	Annotation of Swissmedic Label for maraviroc and CYP3A5	Swissmedic		Actionable PGx							maraviroc	CYP3A5	CYP3A5*1	
https://www.pharmgkb.org/labelAnnotation/PA166182949		PA166182949	Annotation of EMA Label for erlotinib and UGT1A1	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erlotinib	UGT1A1		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166183219		PA166183219	Annotation of EMA Label for mirabegron and CYP2D6	EMA		No Clinical PGx							mirabegron	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166183563		PA166183563	Annotation of Swissmedic Label for abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166161536		PA166161536	Annotation of PMDA Label for atazanavir and CYP2C19	PMDA		Actionable PGx							atazanavir	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166182766		PA166182766	"Annotation of FDA Label for fosphenytoin and CYP2C19, CYP2C9, HLA-B"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	fosphenytoin	CYP2C19; CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166183441		PA166183441	Annotation of EMA Label for umeclidinium and CYP2D6	EMA		No Clinical PGx							umeclidinium	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166182928		PA166182928	Annotation of EMA Label for binimetinib and BRAF	EMA		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166177479		PA166177479	Annotation of FDA Label for cariprazine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							cariprazine	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166182942		PA166182942	Annotation of EMA Label for dacomitinib and EGFR	EMA		Testing Required					Cancer Genome		dacomitinib	EGFR		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166182953		PA166182953	Annotation of EMA Label for ivacaftor / lumacaftor and CFTR	EMA		Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183423		PA166183423	"Annotation of EMA Label for rucaparib and BRCA1, BRCA2"	EMA		Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166182934		PA166182934	Annotation of EMA Label for cerliponase alfa and TPP1	EMA									cerliponase alfa	TPP1		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166182932		PA166182932	Annotation of EMA Label for brivaracetam and CYP2C19	EMA		Informative PGx							brivaracetam	CYP2C19		7/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166170937		PA166170937	Annotation of FDA Label for trametinib and G6PD	FDA	On FDA Biomarker List								trametinib	G6PD		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166184917		PA166184917	Annotation of FDA Label for avatrombopag and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							avatrombopag	CYP2C9	CYP2C9*2; CYP2C9*3	7/11/2024
https://www.pharmgkb.org/labelAnnotation/PA166160668		PA166160668	Annotation of PMDA Label for allopurinol and HLA-B	PMDA		Informative PGx							allopurinol	HLA-B	HLA-B*58:01	
https://www.pharmgkb.org/labelAnnotation/PA166183200		PA166183200	Annotation of EMA Label for midostaurin and FLT3	EMA		Testing Required					Cancer Genome		midostaurin	FLT3		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183184		PA166183184	Annotation of EMA Label for lorlatinib and ALK	EMA		Testing Required					Cancer Genome		lorlatinib	ALK		5/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166177516		PA166177516	Annotation of FDA Label for neratinib and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		neratinib	ERBB2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166159586		PA166159586	Annotation of HCSC Label for aliskiren and ABCB1	HCSC									aliskiren	ABCB1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166183784		PA166183784	Annotation of Swissmedic Label for amifampridine phosphate and NAT2	Swissmedic		Actionable PGx							amifampridine phosphate	NAT2		
https://www.pharmgkb.org/labelAnnotation/PA166183782		PA166183782	Annotation of Swissmedic Label for aspirin and G6PD	Swissmedic		Actionable PGx							aspirin	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184232		PA166184232	Annotation of Swissmedic Label for venlafaxine and CYP2D6	Swissmedic		Actionable PGx							venlafaxine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166159584		PA166159584	Annotation of HCSC Label for afutuzumab and MS4A1	HCSC							Cancer Genome		afutuzumab	MS4A1		8/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166183249		PA166183249	"Annotation of EMA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2"	EMA		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166170930		PA166170930	"Annotation of FDA Label for dabrafenib and HRAS, KRAS, NRAS"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS		11/30/2023
https://www.pharmgkb.org/labelAnnotation/PA166183251		PA166183251	Annotation of EMA Label for raltegravir and UGT1A1	EMA		No Clinical PGx							raltegravir	UGT1A1		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166183248		PA166183248	Annotation of EMA Label for palonosetron and CYP2D6	EMA		No Clinical PGx							palonosetron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166169877		PA166169877	Annotation of FDA Label for avelumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		avelumab	CD274		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166183783		PA166183783	Annotation of Swissmedic Label for allopurinol and HLA-B	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	allopurinol	HLA-B	HLA-B*58:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166163433		PA166163433	Annotation of FDA Label for eteplirsen and DMD	FDA	On FDA Biomarker List	Testing Required							eteplirsen	DMD		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166183172		PA166183172	"Annotation of EMA Label for lapatinib and HLA-DQA1, HLA-DRB1"	EMA		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
https://www.pharmgkb.org/labelAnnotation/PA166183220		PA166183220	"Annotation of EMA Label for neratinib and ERBB2, ESR1, ESR2, PGR"	EMA		Testing Required					Cancer Genome		neratinib	ERBB2; ESR1; ESR2; PGR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166160153		PA166160153	Annotation of PMDA Label for celecoxib and CYP2C9	PMDA		Actionable PGx							celecoxib	CYP2C9		
https://www.pharmgkb.org/labelAnnotation/PA166160226		PA166160226	Annotation of PMDA Label for codeine and CYP2D6	PMDA		Actionable PGx							codeine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166160683		PA166160683	Annotation of PMDA Label for dapsone and G6PD	PMDA		Actionable PGx							dapsone	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160162		PA166160162	Annotation of PMDA Label for efavirenz and CYP2B6	PMDA		Actionable PGx							efavirenz	CYP2B6		
https://www.pharmgkb.org/labelAnnotation/PA166160712		PA166160712	Annotation of PMDA Label for fesoterodine and CYP2D6	PMDA		Actionable PGx							fesoterodine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166160717		PA166160717	Annotation of PMDA Label for letrozole and CYP2A6	PMDA		Actionable PGx							letrozole	CYP2A6		
https://www.pharmgkb.org/labelAnnotation/PA166160719		PA166160719	Annotation of PMDA Label for nalidixic acid and G6PD	PMDA		Actionable PGx							nalidixic acid	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160845		PA166160845	Annotation of PMDA Label for perphenazine and CYP2D6	PMDA		Actionable PGx							perphenazine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166160846		PA166160846	Annotation of PMDA Label for rabeprazole and CYP2C19	PMDA		Actionable PGx							rabeprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166160847		PA166160847	Annotation of PMDA Label for sulfadiazine and G6PD	PMDA		Actionable PGx							sulfadiazine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160848		PA166160848	Annotation of PMDA Label for sulfamethoxazole / trimethoprim and G6PD	PMDA		Actionable PGx							sulfamethoxazole / trimethoprim	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160849		PA166160849	Annotation of PMDA Label for sulfasalazine and G6PD	PMDA		Actionable PGx							sulfasalazine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160850		PA166160850	Annotation of PMDA Label for tetrabenazine and CYP2D6	PMDA		Actionable PGx							tetrabenazine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166160854		PA166160854	Annotation of PMDA Label for moviprep and G6PD	PMDA		Actionable PGx							moviprep	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160856		PA166160856	Annotation of PMDA Label for voriconazole and CYP2C19	PMDA		Actionable PGx							voriconazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166160709		PA166160709	Annotation of PMDA Label for eliglustat and CYP2D6	PMDA		Testing Required							eliglustat	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166160710		PA166160710	Annotation of PMDA Label for erlotinib and EGFR	PMDA		Testing Required							erlotinib	EGFR		
https://www.pharmgkb.org/labelAnnotation/PA166160851		PA166160851	Annotation of PMDA Label for vemurafenib and BRAF	PMDA		Testing Required							vemurafenib	BRAF		
https://www.pharmgkb.org/labelAnnotation/PA166160669		PA166160669	"Annotation of PMDA Label for escitalopram and CYP2C19, CYP2D6"	PMDA		Actionable PGx							escitalopram	CYP2C19; CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166152939		PA166152939	Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / lumacaftor	CFTR	rs113993960	10/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166179870		PA166179870	Annotation of FDA Label for binimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	10/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166183881		PA166183881	Annotation of Swissmedic Label for mivacurium and BCHE	Swissmedic		Actionable PGx							mivacurium	BCHE		11/15/2022
https://www.pharmgkb.org/labelAnnotation/PA166184130		PA166184130	Annotation of Swissmedic Label for dapoxetine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dapoxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184115		PA166184115	Annotation of Swissmedic Label for carbamazepine and HLA-A	Swissmedic		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-A	HLA-A*31:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184445		PA166184445	Annotation of Swissmedic Label for escitalopram and CYP2C19	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	escitalopram	CYP2C19		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184378		PA166184378	Annotation of Swissmedic Label for irinotecan and UGT1A1	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166183901		PA166183901	Annotation of Swissmedic Label for moxifloxacin and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	moxifloxacin	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184082		PA166184082	Annotation of Swissmedic Label for nicorandil and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	nicorandil	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184128		PA166184128	Annotation of Swissmedic Label for acetaminophen / codeine and G6PD	Swissmedic		Actionable PGx							acetaminophen / codeine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184109		PA166184109	Annotation of Swissmedic Label for aripiprazole and CYP2D6	Swissmedic		Actionable PGx							aripiprazole	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184119		PA166184119	Annotation of Swissmedic Label for celecoxib and CYP2C9	Swissmedic		Actionable PGx							celecoxib	CYP2C9	CYP2C9*1; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166184131		PA166184131	Annotation of Swissmedic Label for darifenacin and CYP2D6	Swissmedic		Actionable PGx							darifenacin	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184444		PA166184444	Annotation of Swissmedic Label for eletriptan and CYP2D6	Swissmedic		Informative PGx							eletriptan	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184448		PA166184448	Annotation of Swissmedic Label for flucloxacillin and HLA-B	Swissmedic		Actionable PGx							flucloxacillin	HLA-B	HLA-B*57:01	
https://www.pharmgkb.org/labelAnnotation/PA166184108		PA166184108	Annotation of Swissmedic Label for fluorouracil / salicylic acid and DPYD	Swissmedic		Testing Recommended							fluorouracil / salicylic acid	DPYD		
https://www.pharmgkb.org/labelAnnotation/PA166184453		PA166184453	Annotation of Swissmedic Label for fluvoxamine and CYP2D6	Swissmedic		Actionable PGx							fluvoxamine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184458		PA166184458	Annotation of Swissmedic Label for glimepiride and G6PD	Swissmedic		Actionable PGx							glimepiride	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184377		PA166184377	Annotation of Swissmedic Label for indacaterol and UGT1A1	Swissmedic		Informative PGx							indacaterol	UGT1A1	UGT1A1*28	
https://www.pharmgkb.org/labelAnnotation/PA166184382		PA166184382	Annotation of Swissmedic Label for lansoprazole and CYP2C19	Swissmedic		Actionable PGx							lansoprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166184385		PA166184385	Annotation of Swissmedic Label for lesinurad and CYP2C9	Swissmedic		Informative PGx							lesinurad	CYP2C9	CYP2C9*1; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166183790		PA166183790	Annotation of Swissmedic Label for metoprolol and CYP2D6	Swissmedic		Actionable PGx							metoprolol	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166183810		PA166183810	Annotation of Swissmedic Label for mirabegron and CYP2D6	Swissmedic		Informative PGx							mirabegron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184118		PA166184118	Annotation of Swissmedic Label for carvedilol and CYP2D6	Swissmedic		Informative PGx							carvedilol	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166184127		PA166184127	Annotation of Swissmedic Label for acetaminophen / codeine and CYP2D6	Swissmedic		Testing Required	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / codeine	CYP2D6		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166182947		PA166182947	Annotation of EMA Label for elosulfase alfa and GALNS	EMA		Testing Required							elosulfase alfa	GALNS		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166182929		PA166182929	Annotation of EMA Label for binimetinib and UGT1A1	EMA		No Clinical PGx							binimetinib	UGT1A1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166184156		PA166184156	Annotation of Swissmedic Label for norfloxacin and G6PD	Swissmedic		Actionable PGx							norfloxacin	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184459		PA166184459	Annotation of Swissmedic Label for nitroglycerin and G6PD	Swissmedic		Actionable PGx							nitroglycerin	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184159		PA166184159	Annotation of Swissmedic Label for omeprazole and CYP2C19	Swissmedic		Actionable PGx							omeprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166184222		PA166184222	Annotation of Swissmedic Label for pantoprazole and CYP2C19	Swissmedic		Informative PGx							pantoprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166182930		PA166182930	Annotation of EMA Label for brexpiprazole and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184402		PA166184402	Annotation of Swissmedic Label for ranolazine and CYP2D6	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	ranolazine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184373		PA166184373	Annotation of Swissmedic Label for piroxicam and CYP2C9	Swissmedic		Actionable PGx							piroxicam	CYP2C9	CYP2C9*2; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166184381		PA166184381	Annotation of Swissmedic Label for prilocaine and G6PD	Swissmedic		Actionable PGx							prilocaine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184234		PA166184234	Annotation of Swissmedic Label for vernakalant and CYP2D6	Swissmedic		Informative PGx							vernakalant	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184504		PA166184504	Annotation of Swissmedic Label for zidovudine / lamivudine / abacavir and HLA-B	Swissmedic		Testing Required	Prescribing Info					Prescribing	zidovudine / lamivudine / abacavir	HLA-B	HLA-B*57:01	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184110		PA166184110	Annotation of Swissmedic Label for vitamin c and G6PD	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vitamin c	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166182926		PA166182926	Annotation of EMA Label for atezolizumab and CD274	EMA		Testing Required					Cancer Genome		atezolizumab	CD274		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166184441		PA166184441	"Annotation of Swissmedic Label for dolutegravir and CYP3A4, CYP3A5, NR1I2, UGT1A1"	Swissmedic		Informative PGx							dolutegravir	CYP3A4; CYP3A5; NR1I2; UGT1A1		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166182924		PA166182924	Annotation of EMA Label for alectinib and ALK	EMA		Testing Required					Cancer Genome		alectinib	ALK		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166182951		PA166182951	Annotation of EMA Label for glyburide and G6PD	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166183183		PA166183183	"Annotation of EMA Label for lidocaine / prilocaine and CYB5R3, G6PD"	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166182950		PA166182950	Annotation of EMA Label for gefitinib and CYP2D6	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166182945		PA166182945	Annotation of EMA Label for efavirenz and CYP2B6	EMA		Informative PGx							efavirenz	CYP2B6	CYP2B6*1; CYP2B6*6; rs3745274	
https://www.pharmgkb.org/labelAnnotation/PA166183171		PA166183171	Annotation of EMA Label for lacosamide and CYP2C19	EMA		No Clinical PGx							lacosamide	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166183247		PA166183247	"Annotation of EMA Label for palbociclib and ERBB2, ESR1, ESR2, PGR"	EMA		Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2; PGR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166105319		PA166105319	"Annotation of EMA Label for panitumumab and KRAS, NRAS"	EMA		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166122067		PA166122067	"Annotation of EMA Label for ponatinib and ABL1, BCR"	EMA		Testing Required					Cancer Genome		ponatinib	ABL1; BCR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166277781		PA166277781	Annotation of EMA Label for tebentafusp and HLA-A	EMA		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166272661		PA166272661	"Annotation of HCSC Label for abemaciclib and ERBB2, ESR1, ESR2"	HCSC		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166184123		PA166184123	"Annotation of Swissmedic Label for citalopram and CYP2C19, CYP2D6"	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19; CYP2D6		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184345		PA166184345	"Annotation of Swissmedic Label for phenytoin and CYP2C9, HLA-B"	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	phenytoin	CYP2C9; HLA-B	HLA-B*15:02	2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184424		PA166184424	Annotation of Swissmedic Label for thioguanine and TPMT	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	thioguanine	TPMT		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166160039		PA166160039	Annotation of FDA Label for evolocumab	FDA	On FDA Biomarker List								evolocumab			9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166293361		PA166293361	Annotation of FDA Label for desmopressin and F8	FDA	On FDA Biomarker List	Testing Required							desmopressin	F8		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166293681		PA166293681	"Annotation of FDA Label for trastuzumab deruxtecan and ESR1, ESR2"	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab deruxtecan	ESR1; ESR2		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166163412		PA166163412	Annotation of FDA Label for ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								ombitasvir / paritaprevir / ritonavir	IFNL3		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166163435		PA166163435	Annotation of FDA Label for olaratumab and PDGFRA	FDA	On FDA Biomarker List						Cancer Genome		olaratumab	PDGFRA		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166235881		PA166235881	Annotation of FDA Label for margetuximab and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		margetuximab	ERBB2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166293742		PA166293742	Annotation of FDA Label for mirvetuximab soravtansine and FOLR1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mirvetuximab soravtansine	FOLR1		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166293921		PA166293921	Annotation of FDA Label for olutasidenib and IDH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olutasidenib	IDH1	rs121913499; rs121913500	8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166294401		PA166294401	Annotation of HCSC Label for evolocumab	HCSC									evolocumab			8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166293301		PA166293301	"Annotation of FDA Label for betaine and CBS, MMADHC, MTHFR"	FDA	On FDA Biomarker List								betaine	CBS; MMADHC; MTHFR		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166293961		PA166293961	"Annotation of HCSC Label for betaine and CBS, MMADHC, MTHFR"	HCSC									betaine	CBS; MMADHC; MTHFR		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166293981		PA166293981	Annotation of HCSC Label for desmopressin and F8	HCSC		Testing Required							desmopressin	F8		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166293941		PA166293941	"Annotation of EMA Label for betaine and CBS, MMADHC, MTHFR"	EMA									betaine	CBS; MMADHC; MTHFR		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166294041		PA166294041	Annotation of EMA Label for durvalumab and CD274	EMA		Testing Required					Cancer Genome		durvalumab	CD274		5/10/2024
https://www.pharmgkb.org/labelAnnotation/PA166294981		PA166294981	Annotation of EMA Label for pemigatinib and FGFR2	EMA		Testing Required					Cancer Genome		pemigatinib	FGFR2		
https://www.pharmgkb.org/labelAnnotation/PA166295001		PA166295001	Annotation of HCSC Label for pemigatinib and FGFR2	HCSC		Testing Required					Cancer Genome		pemigatinib	FGFR2		
https://www.pharmgkb.org/labelAnnotation/PA166104811		PA166104811	Annotation of FDA Label for quinidine and CYP2D6	FDA	On FDA Biomarker List								quinidine	CYP2D6		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166104845		PA166104845	Annotation of FDA Label for dapsone and CYB5R3	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166295822		PA166295822	Annotation of FDA Label for teclistamab	FDA	On FDA Biomarker List						Cancer Genome		teclistamab			8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166104788		PA166104788	Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6	FDA		Informative PGx							fluoxetine / olanzapine	CYP2D6		12/17/2013
https://www.pharmgkb.org/labelAnnotation/PA166104789		PA166104789	Annotation of FDA Label for gefitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gefitinib	EGFR	rs121434568	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104833		PA166104833	Annotation of FDA Label for abacavir and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	5/8/2019
https://www.pharmgkb.org/labelAnnotation/PA166104812		PA166104812	Annotation of FDA Label for protriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							protriptyline	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104806		PA166104806	Annotation of FDA Label for tolterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tolterodine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104826		PA166104826	"Annotation of FDA Label for cetuximab and BRAF, EGFR, KRAS, NRAS"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cetuximab	BRAF; EGFR; KRAS; NRAS		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104784		PA166104784	Annotation of FDA Label for diazepam and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							diazepam	CYP2C19		12/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166104831		PA166104831	Annotation of FDA Label for irinotecan and UGT1A1	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	8/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166104828		PA166104828	Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2	FDA	On FDA Biomarker List	Informative PGx							hydralazine / isosorbide dinitrate	NAT2		9/8/2023
https://www.pharmgkb.org/labelAnnotation/PA166104777		PA166104777	Annotation of FDA Label for clopidogrel and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19		7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166104813		PA166104813	Annotation of FDA Label for carvedilol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							carvedilol	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104851		PA166104851	Annotation of FDA Label for ticagrelor and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							ticagrelor	CYP2C19		3/16/2017
https://www.pharmgkb.org/labelAnnotation/PA166104816		PA166104816	Annotation of FDA Label for esomeprazole and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							esomeprazole	CYP2C19		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104863		PA166104863	Annotation of FDA Label for dexlansoprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							dexlansoprazole	CYP2C19		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104799		PA166104799	Annotation of FDA Label for tramadol and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tramadol	CYP2D6		5/1/2017
https://www.pharmgkb.org/labelAnnotation/PA166104859		PA166104859	"Annotation of FDA Label for crizotinib and ALK, ROS1"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		crizotinib	ALK; ROS1		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104808		PA166104808	"Annotation of FDA Label for nelfinavir and CYP2C19, CYP3A4, CYP3A5"	FDA	Formerly on FDA Biomarker List								nelfinavir	CYP2C19; CYP3A4; CYP3A5		8/29/2024
https://www.pharmgkb.org/labelAnnotation/PA166104797		PA166104797	"Annotation of FDA Label for letrozole and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104781		PA166104781	"Annotation of FDA Label for dasatinib and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104836		PA166104836	Annotation of FDA Label for metoprolol and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							metoprolol	CYP2D6		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166104818		PA166104818	Annotation of FDA Label for voriconazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							voriconazole	CYP2C19		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104820		PA166104820	"Annotation of FDA Label for doxepin and CYP2C19, CYP2D6"	FDA	On FDA Biomarker List	Informative PGx							doxepin	CYP2C19; CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104842		PA166104842	"Annotation of FDA Label for nilotinib and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nilotinib	ABL1; BCR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104854		PA166104854	Annotation of FDA Label for fluvoxamine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	fluvoxamine	CYP2D6		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166104858		PA166104858	Annotation of FDA Label for vemurafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		vemurafenib	BRAF	rs113488022	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104796		PA166104796	Annotation of FDA Label for trastuzumab emtansine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104857		PA166104857	Annotation of FDA Label for trimipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							trimipramine	CYP2D6		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166104798		PA166104798	Annotation of FDA Label for propranolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propranolol	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104802		PA166104802	Annotation of FDA Label for capecitabine and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD		12/19/2022
https://www.pharmgkb.org/labelAnnotation/PA166104815		PA166104815	Annotation of FDA Label for clozapine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	clozapine	CYP2D6		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166104848		PA166104848	Annotation of FDA Label for rabeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							rabeprazole	CYP2C19		10/10/2019
https://www.pharmgkb.org/labelAnnotation/PA166104800		PA166104800	Annotation of FDA Label for indacaterol and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							indacaterol	UGT1A1		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104810		PA166104810	"Annotation of FDA Label for mercaptopurine and NUDT15, TPMT"	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	NUDT15*2; NUDT15*3; TPMT*2; TPMT*3A; TPMT*3C	6/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166104864		PA166104864	Annotation of FDA Label for paroxetine and CYP2D6	FDA	On FDA Biomarker List								paroxetine	CYP2D6		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166104855		PA166104855	Annotation of FDA Label for boceprevir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							boceprevir	IFNL3	rs12979860	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104783		PA166104783	"Annotation of FDA Label for rasburicase and CYB5R1, CYB5R2, CYB5R3, CYB5R4"	FDA	On FDA Biomarker List	No Clinical PGx							rasburicase	CYB5R1; CYB5R2; CYB5R3; CYB5R4		3/21/2016
https://www.pharmgkb.org/labelAnnotation/PA166104803		PA166104803	Annotation of FDA Label for maraviroc and CCR5	FDA	Formerly on FDA Biomarker List								maraviroc	CCR5		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166104776		PA166104776	"Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	warfarin	CYP2C9; PROC; PROS1; VKORC1	CYP2C9*1; CYP2C9*2; CYP2C9*3; rs9923231	12/12/2023
https://www.pharmgkb.org/labelAnnotation/PA166104906		PA166104906	Annotation of FDA Label for probenecid and G6PD	FDA	On FDA Biomarker List	Informative PGx							probenecid	G6PD		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104877		PA166104877	Annotation of FDA Label for mycophenolic acid and HPRT1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104917		PA166104917	"Annotation of FDA Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5"	FDA	On FDA Biomarker List	No Clinical PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104875		PA166104875	Annotation of FDA Label for clomipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							clomipramine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166105213		PA166105213	Annotation of FDA Label for oxcarbazepine and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	4/16/2019
https://www.pharmgkb.org/labelAnnotation/PA166105222		PA166105222	Annotation of FDA Label for piroxicam and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	piroxicam	CYP2C9		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166105023		PA166105023	Annotation of FDA Label for rosuvastatin and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							rosuvastatin	SLCO1B1	rs4149056	3/15/2017
https://www.pharmgkb.org/labelAnnotation/PA166104893		PA166104893	Annotation of FDA Label for perphenazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							perphenazine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104921		PA166104921	Annotation of FDA Label for omeprazole and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							omeprazole	CYP2C19		3/16/2017
https://www.pharmgkb.org/labelAnnotation/PA166105178		PA166105178	"Annotation of FDA Label for lidocaine / prilocaine and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine / prilocaine	CYB5R3; G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166104901		PA166104901	Annotation of FDA Label for pantoprazole and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pantoprazole	CYP2C19		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166105028		PA166105028	Annotation of FDA Label for nebivolol and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							nebivolol	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166104867		PA166104867	Annotation of FDA Label for telaprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							telaprevir	IFNL3	rs12979860	10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166114907		PA166114907	"Annotation of FDA Label for bosutinib and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104868		PA166104868	Annotation of FDA Label for modafinil and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							modafinil	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104913		PA166104913	"Annotation of FDA Label for everolimus and ERBB2, ESR1, ESR2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104886		PA166104886	Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info			Other Prescribing Guidance		Prescribing	dextromethorphan / quinidine	CYP2D6		10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166104912		PA166104912	"Annotation of FDA Label for eltrombopag and F5, SERPINC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166114905		PA166114905	Annotation of FDA Label for belimumab and TNFSF13B	FDA	Formerly on FDA Biomarker List								belimumab	TNFSF13B		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166104888		PA166104888	Annotation of FDA Label for nortriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							nortriptyline	CYP2D6		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166105059		PA166105059	Annotation of FDA Label for ofatumumab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ofatumumab	MS4A1		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166104866		PA166104866	Annotation of FDA Label for pravastatin and APOE	FDA	Formerly on FDA Biomarker List								pravastatin	APOE		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166104892		PA166104892	Annotation of FDA Label for sulfasalazine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166114912		PA166114912	Annotation of FDA Label for dabrafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dabrafenib	BRAF	rs113488022	11/30/2023
https://www.pharmgkb.org/labelAnnotation/PA166114928		PA166114928	Annotation of FDA Label for mipomersen and LDLR	FDA	Formerly on FDA Biomarker List								mipomersen	LDLR		8/20/2024
https://www.pharmgkb.org/labelAnnotation/PA166182751		PA166182751	Annotation of FDA Label for mepivacaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	mepivacaine	G6PD		10/3/2023
https://www.pharmgkb.org/labelAnnotation/PA166179855		PA166179855	"Annotation of FDA Label for avatrombopag and F2, F5, PROC, PROS1, SERPINC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166169878		PA166169878	Annotation of FDA Label for brigatinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		brigatinib	ALK		8/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166160009		PA166160009	"Annotation of FDA Label for pembrolizumab and ALK, CD274, EGFR, ERBB2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		11/30/2023
https://www.pharmgkb.org/labelAnnotation/PA166177475		PA166177475	"Annotation of FDA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166170936		PA166170936	"Annotation of FDA Label for tamoxifen and F2, F5"	FDA	On FDA Biomarker List	No Clinical PGx							tamoxifen	F2; F5		
https://www.pharmgkb.org/labelAnnotation/PA166153432		PA166153432	"Annotation of FDA Label for flibanserin and CYP2C9, CYP2D6"	FDA	On FDA Biomarker List	Informative PGx							flibanserin	CYP2C9; CYP2D6		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166151853		PA166151853	Annotation of FDA Label for nilotinib and UGT1A1	FDA	On FDA Biomarker List	Informative PGx							nilotinib	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166177509		PA166177509	"Annotation of FDA Label for formoterol and CYP2C19, CYP2D6"	FDA	On FDA Biomarker List	No Clinical PGx							formoterol	CYP2C19; CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166182765		PA166182765	Annotation of FDA Label for flutamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flutamide	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166180000		PA166180000	Annotation of FDA Label for meclizine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	meclizine	CYP2D6		10/21/2019
https://www.pharmgkb.org/labelAnnotation/PA166181925		PA166181925	Annotation of FDA Label for tamoxifen and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							tamoxifen	CYP2D6		10/9/2019
https://www.pharmgkb.org/labelAnnotation/PA166129553		PA166129553	Annotation of FDA Label for belinostat and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	belinostat	UGT1A1		5/9/2019
https://www.pharmgkb.org/labelAnnotation/PA166127663		PA166127663	Annotation of FDA Label for divalproex sodium and POLG	FDA	Formerly on FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	divalproex sodium	POLG		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166182739		PA166182739	Annotation of FDA Label for tafenoquine and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	tafenoquine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160021		PA166160021	Annotation of FDA Label for cabozantinib and RET	FDA	On FDA Biomarker List						Cancer Genome		cabozantinib	RET		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166177512		PA166177512	"Annotation of FDA Label for inotuzumab ozogamicin and ABL1, BCR"	FDA	On FDA Biomarker List						Cancer Genome		inotuzumab ozogamicin	ABL1; BCR		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166182729		PA166182729	Annotation of FDA Label for amoxapine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amoxapine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166170957		PA166170957	"Annotation of FDA Label for vemurafenib and HRAS, KRAS, NRAS"	FDA	On FDA Biomarker List						Cancer Genome		vemurafenib	HRAS; KRAS; NRAS		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166170048		PA166170048	"Annotation of FDA Label for ribociclib and ERBB2, ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166170932		PA166170932	Annotation of FDA Label for pembrolizumab and BRAF	FDA	On FDA Biomarker List						Cancer Genome		pembrolizumab	BRAF	rs113488022	11/30/2023
https://www.pharmgkb.org/labelAnnotation/PA166153492		PA166153492	Annotation of FDA Label for brivaracetam and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brivaracetam	CYP2C19		7/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166160061		PA166160061	Annotation of FDA Label for dinutuximab and MYCN	FDA	On FDA Biomarker List						Cancer Genome		dinutuximab	MYCN		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166182760		PA166182760	"Annotation of FDA Label for docetaxel and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		docetaxel	ESR1; ESR2; PGR		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166163422		PA166163422	Annotation of FDA Label for dronabinol and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dronabinol	CYP2C9		
https://www.pharmgkb.org/labelAnnotation/PA166115363		PA166115363	Annotation of FDA Label for succimer and G6PD	FDA	On FDA Biomarker List								succimer	G6PD		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166182768		PA166182768	Annotation of FDA Label for gilteritinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gilteritinib	FLT3		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166114931		PA166114931	"Annotation of FDA Label for ponatinib and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ponatinib	ABL1; BCR	rs121913459	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166163430		PA166163430	"Annotation of FDA Label for isosorbide dinitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4"	FDA	On FDA Biomarker List	Informative PGx							isosorbide dinitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166114941		PA166114941	Annotation of FDA Label for pravastatin and LDLR	FDA	Formerly on FDA Biomarker List								pravastatin	LDLR		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166182724		PA166182724	"Annotation of FDA Label for ixabepilone and ERBB2, ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		ixabepilone	ERBB2; ESR1; ESR2; PGR		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166163417		PA166163417	Annotation of FDA Label for sofosbuvir / velpatasvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir	IFNL3	rs12979860	8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166163420		PA166163420	"Annotation of FDA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53"	FDA	On FDA Biomarker List						Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166182734		PA166182734	"Annotation of FDA Label for larotrectinib and NTRK1, NTRK2, NTRK3"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		5/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166170931		PA166170931	"Annotation of FDA Label for midostaurin and KIT, NPM1"	FDA	On FDA Biomarker List						Cancer Genome		midostaurin	KIT; NPM1		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166163429		PA166163429	"Annotation of FDA Label for atezolizumab and ALK, BRAF, CD274, EGFR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		atezolizumab	ALK; BRAF; CD274; EGFR	rs113488022	8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166182757		PA166182757	Annotation of FDA Label for inotersen and TTR	FDA	On FDA Biomarker List								inotersen	TTR		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166160046		PA166160046	Annotation of FDA Label for cobimetinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166131627		PA166131627	Annotation of FDA Label for osimertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166115365		PA166115365	Annotation of FDA Label for trametinib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trametinib	BRAF	rs113488022	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166163428		PA166163428	Annotation of FDA Label for ledipasvir / sofosbuvir and IFNL3	FDA	On FDA Biomarker List								ledipasvir / sofosbuvir	IFNL3		9/6/2023
https://www.pharmgkb.org/labelAnnotation/PA166169920		PA166169920	"Annotation of FDA Label for niraparib and BRCA1, BRCA2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		niraparib	BRCA1; BRCA2		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166114944		PA166114944	Annotation of FDA Label for regorafenib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		regorafenib	KRAS		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166163421		PA166163421	Annotation of FDA Label for daclatasvir and IFNL3	FDA	On FDA Biomarker List	No Clinical PGx							daclatasvir	IFNL3		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166127644		PA166127644	Annotation of HCSC Label for capecitabine and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	capecitabine	DPYD	DPYD c.1905+1G>A (*2A)	3/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166238981		PA166238981	"Annotation of FDA Label for synthetic conjugated estrogens, A and PROC, PROS1, SERPINC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	"synthetic conjugated estrogens, A"	PROC; PROS1; SERPINC1		
https://www.pharmgkb.org/labelAnnotation/PA166293421		PA166293421	"Annotation of FDA Label for pemigatinib and FGFR1, FGFR2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemigatinib	FGFR1; FGFR2		
https://www.pharmgkb.org/labelAnnotation/PA166190141		PA166190141	Annotation of FDA Label for enfortumab vedotin and NECTIN4	FDA	Formerly on FDA Biomarker List						Cancer Genome		enfortumab vedotin	NECTIN4		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166185180		PA166185180	Annotation of FDA Label for nusinersen and SMN2	FDA	On FDA Biomarker List								nusinersen	SMN2		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166269301		PA166269301	Annotation of FDA Label for maralixibat and JAG1	FDA	On FDA Biomarker List								maralixibat	JAG1		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166225042		PA166225042	Annotation of FDA Label for rimegepant and CYP2C9	FDA	On FDA Biomarker List	No Clinical PGx							rimegepant	CYP2C9		3/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166182769		PA166182769	Annotation of FDA Label for hydroxychloroquine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	hydroxychloroquine	G6PD		9/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166235601		PA166235601	"Annotation of FDA Label for lonafarnib and LMNA, ZMPSTE24"	FDA	On FDA Biomarker List	Testing Required							lonafarnib	LMNA; ZMPSTE24		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166278281		PA166278281	Annotation of FDA Label for estradiol valerate	FDA	On FDA Biomarker List								estradiol valerate			8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166235441		PA166235441	"Annotation of FDA Label for bupivacaine and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166182886		PA166182886	Annotation of FDA Label for migalastat and GLA	FDA	On FDA Biomarker List	Testing Required							migalastat	GLA		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166225101		PA166225101	Annotation of FDA Label for sacituzumab govitecan and UGT1A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sacituzumab govitecan	UGT1A1	UGT1A1*28	10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166182890		PA166182890	"Annotation of FDA Label for olaparib and ESR1, ESR2, PGR, PPP2R2A"	FDA	On FDA Biomarker List						Cancer Genome		olaparib	ESR1; ESR2; PGR; PPP2R2A		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166190101		PA166190101	Annotation of FDA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908752; rs121908753; rs121908755; rs121908757; rs121909005; rs121909013; rs121909020; rs121909041; rs141033578; rs150212784; rs186045772; rs193922525; rs200321110; rs202179988; rs267606723; rs368505753; rs397508256; rs397508288; rs397508442; rs397508513; rs397508537; rs397508759; rs74503330; rs74551128; rs75527207; rs75541969; rs77834169; rs77932196; rs78655421; rs78769542; rs80282562	10/12/2023
https://www.pharmgkb.org/labelAnnotation/PA166190761		PA166190761	Annotation of FDA Label for upadacitinib and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							upadacitinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166190023		PA166190023	Annotation of FDA Label for luspatercept and HBB	FDA	On FDA Biomarker List								luspatercept	HBB		3/31/2024
https://www.pharmgkb.org/labelAnnotation/PA166225121		PA166225121	Annotation of FDA Label for selpercatinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		selpercatinib	RET		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166185168		PA166185168	Annotation of FDA Label for pitolisant and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	pitolisant	CYP2D6		2/11/2020
https://www.pharmgkb.org/labelAnnotation/PA166225142		PA166225142	"Annotation of FDA Label for tucatinib and ERBB2, HRAS, KRAS, NRAS"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tucatinib	ERBB2; HRAS; KRAS; NRAS		10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166190701		PA166190701	"Annotation of FDA Label for givosiran and CPOX, HMBS, PPOX"	FDA	On FDA Biomarker List								givosiran	CPOX; HMBS; PPOX		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166224202		PA166224202	Annotation of FDA Label for capmatinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capmatinib	MET		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166191501		PA166191501	Annotation of FDA Label for lenvatinib	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lenvatinib			8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166236521		PA166236521	Annotation of FDA Label for viltolarsen and DMD	FDA	On FDA Biomarker List	Testing Required							viltolarsen	DMD		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166236001		PA166236001	Annotation of FDA Label for sodium oxybate and ALDH5A1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sodium oxybate	ALDH5A1		4/22/2022
https://www.pharmgkb.org/labelAnnotation/PA166121327		PA166121327	Annotation of EMA Label for pegloticase and G6PD	EMA		Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		3/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166278321		PA166278321	Annotation of FDA Label for ganaxolone and CDKL5	FDA	On FDA Biomarker List	Testing Required							ganaxolone	CDKL5		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166169884		PA166169884	"Annotation of FDA Label for durvalumab and ALK, CD274, EGFR, PDCD1"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		durvalumab	ALK; CD274; EGFR; PDCD1		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166191581		PA166191581	"Annotation of FDA Label for ipilimumab and ALK, CD274, EGFR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ipilimumab	ALK; CD274; EGFR		12/4/2023
https://www.pharmgkb.org/labelAnnotation/PA166182719		PA166182719	Annotation of FDA Label for ipilimumab and HLA-A	FDA	On FDA Biomarker List	No Clinical PGx							ipilimumab	HLA-A	HLA-A*02:01	12/4/2023
https://www.pharmgkb.org/labelAnnotation/PA166123390		PA166123390	Annotation of EMA Label for fampridine and SLC22A2	EMA									fampridine	SLC22A2		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166123412		PA166123412	Annotation of EMA Label for sunitinib and CYP3A4	EMA									sunitinib	CYP3A4		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166123421		PA166123421	Annotation of EMA Label for atazanavir and CYP2C19	EMA		Informative PGx							atazanavir	CYP2C19		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166123528		PA166123528	Annotation of PMDA Label for atomoxetine and CYP2D6	PMDA		Actionable PGx							atomoxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166123530		PA166123530	Annotation of PMDA Label for azathioprine and TPMT	PMDA		Actionable PGx							azathioprine	TPMT		
https://www.pharmgkb.org/labelAnnotation/PA166123531		PA166123531	Annotation of PMDA Label for capecitabine and DPYD	PMDA		Actionable PGx							capecitabine	DPYD		
https://www.pharmgkb.org/labelAnnotation/PA166123535		PA166123535	Annotation of PMDA Label for clopidogrel and CYP2C19	PMDA		Actionable PGx							clopidogrel	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166123536		PA166123536	Annotation of PMDA Label for crizotinib and ALK	PMDA		Testing Required							crizotinib	ALK		
https://www.pharmgkb.org/labelAnnotation/PA166123538		PA166123538	Annotation of PMDA Label for eltrombopag and SERPINC1	PMDA		Actionable PGx							eltrombopag	SERPINC1		
https://www.pharmgkb.org/labelAnnotation/PA166123539		PA166123539	Annotation of PMDA Label for fluorouracil and DPYD	PMDA		Actionable PGx							fluorouracil	DPYD		
https://www.pharmgkb.org/labelAnnotation/PA166123543		PA166123543	Annotation of PMDA Label for indacaterol and UGT1A1	PMDA		Actionable PGx							indacaterol	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166123526		PA166123526	Annotation of PMDA Label for irinotecan and UGT1A1	PMDA		Testing Recommended							irinotecan	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166123546		PA166123546	Annotation of PMDA Label for mycophenolic acid and HPRT1	PMDA		Actionable PGx							mycophenolic acid	HPRT1		
https://www.pharmgkb.org/labelAnnotation/PA166123547		PA166123547	Annotation of PMDA Label for panitumumab and KRAS	PMDA		Testing Required							panitumumab	KRAS		
https://www.pharmgkb.org/labelAnnotation/PA166123548		PA166123548	Annotation of PMDA Label for rasburicase and G6PD	PMDA		Actionable PGx							rasburicase	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166123550		PA166123550	Annotation of PMDA Label for trastuzumab and ERBB2	PMDA		Testing Required							trastuzumab	ERBB2		
https://www.pharmgkb.org/labelAnnotation/PA166123537		PA166123537	"Annotation of PMDA Label for dasatinib and ABL1, BCR"	PMDA		Testing Required							dasatinib	ABL1; BCR		
https://www.pharmgkb.org/labelAnnotation/PA166127722		PA166127722	Annotation of HCSC Label for trametinib and BRAF	HCSC		Testing Required					Cancer Genome		trametinib	BRAF		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127724		PA166127724	Annotation of HCSC Label for trastuzumab and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127721		PA166127721	Annotation of HCSC Label for tolterodine and CYP2D6	HCSC		Informative PGx							tolterodine	CYP2D6		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166127725		PA166127725	"Annotation of HCSC Label for tretinoin and PML, RARA"	HCSC							Cancer Genome		tretinoin	PML; RARA		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166123408		PA166123408	Annotation of EMA Label for vortioxetine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		9/15/2014
https://www.pharmgkb.org/labelAnnotation/PA166127723		PA166127723	Annotation of HCSC Label for trastuzumab emtansine and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab emtansine	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127731		PA166127731	Annotation of HCSC Label for vortioxetine and CYP2D6	HCSC		Informative PGx							vortioxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127728		PA166127728	Annotation of HCSC Label for vemurafenib and BRAF	HCSC		Testing Required					Cancer Genome		vemurafenib	BRAF		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127727		PA166127727	Annotation of HCSC Label for velaglucerase alfa and GBA	HCSC									velaglucerase alfa	GBA		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166127732		PA166127732	"Annotation of HCSC Label for warfarin and CYP2C9, VKORC1"	HCSC		Informative PGx							warfarin	CYP2C9; VKORC1		
https://www.pharmgkb.org/labelAnnotation/PA166127730		PA166127730	Annotation of HCSC Label for voriconazole and CYP2C19	HCSC		Informative PGx							voriconazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166127729		PA166127729	Annotation of HCSC Label for moviprep and G6PD	HCSC		Informative PGx							moviprep	G6PD		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166129516		PA166129516	"Annotation of HCSC Label for desflurane and CACNA1S, RYR1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		3/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166129515		PA166129515	"Annotation of FDA Label for desflurane and CACNA1S, RYR1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	desflurane	CACNA1S; RYR1		3/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166129449		PA166129449	Annotation of EMA Label for ceritinib and ALK	EMA		Testing Required					Cancer Genome		ceritinib	ALK		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166129448		PA166129448	Annotation of EMA Label for ibrutinib	EMA							Cancer Genome		ibrutinib			8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166123422		PA166123422	Annotation of EMA Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	EMA		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6	CYP2B6*6; rs3745274	9/16/2014
https://www.pharmgkb.org/labelAnnotation/PA166127665		PA166127665	Annotation of HCSC Label for divalproex sodium and POLG	HCSC		Testing Required							divalproex sodium	POLG		
https://www.pharmgkb.org/labelAnnotation/PA166129518		PA166129518	"Annotation of HCSC Label for isoflurane and CACNA1S, RYR1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166127681		PA166127681	Annotation of HCSC Label for ibrutinib	HCSC							Cancer Genome		ibrutinib			8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166123409		PA166123409	Annotation of EMA Label for aliskiren and ABCB1	EMA									aliskiren	ABCB1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166123418		PA166123418	Annotation of EMA Label for posaconazole and CYP3A4	EMA									posaconazole	CYP3A4		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166123419		PA166123419	Annotation of EMA Label for indinavir and CYP3A4	EMA									indinavir	CYP3A4		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166127630		PA166127630	"Annotation of HCSC Label for anastrozole and ESR1, ESR2, PGR"	HCSC							Cancer Genome		anastrozole	ESR1; ESR2; PGR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166127675		PA166127675	Annotation of HCSC Label for galantamine and CYP2D6	HCSC		No Clinical PGx							galantamine	CYP2D6		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166127655		PA166127655	Annotation of HCSC Label for crizotinib and ALK	HCSC		Testing Required					Cancer Genome		crizotinib	ALK		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127673		PA166127673	Annotation of HCSC Label for fesoterodine and CYP2D6	HCSC		Informative PGx							fesoterodine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127669		PA166127669	Annotation of HCSC Label for erlotinib and EGFR	HCSC		Testing Required					Cancer Genome		erlotinib	EGFR		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127674		PA166127674	Annotation of HCSC Label for fluorouracil and DPYD	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		4/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127628		PA166127628	"Annotation of HCSC Label for acetaminophen, tramadol and CYP2D6"	HCSC		Informative PGx							acetaminophen; tramadol	CYP2D6		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166127627		PA166127627	Annotation of HCSC Label for abacavir and HLA-B	HCSC		Testing Required	Prescribing Info		Alternate Drug			Prescribing	abacavir	HLA-B	HLA-B*57:01	2/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166127631		PA166127631	Annotation of HCSC Label for aripiprazole and CYP2D6	HCSC		Informative PGx							aripiprazole	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127629		PA166127629	Annotation of HCSC Label for afatinib and EGFR	HCSC		Testing Required					Cancer Genome		afatinib	EGFR	rs121434568	5/10/2024
https://www.pharmgkb.org/labelAnnotation/PA166127656		PA166127656	Annotation of HCSC Label for dabrafenib and BRAF	HCSC		Testing Required					Cancer Genome		dabrafenib	BRAF		5/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166127653		PA166127653	Annotation of HCSC Label for clopidogrel and CYP2C19	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	clopidogrel	CYP2C19	CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8	7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166127654		PA166127654	Annotation of HCSC Label for codeine and CYP2D6	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	codeine	CYP2D6	CYP2D6*2x2	7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166127677		PA166127677	Annotation of HCSC Label for glyburide and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glyburide	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166127678		PA166127678	Annotation of HCSC Label for glimepiride and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166127676		PA166127676	Annotation of HCSC Label for gefitinib and EGFR	HCSC		Testing Required					Cancer Genome		gefitinib	EGFR		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166127670		PA166127670	Annotation of HCSC Label for esomeprazole and CYP2C19	HCSC		No Clinical PGx							esomeprazole	CYP2C19		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166127667		PA166127667	Annotation of HCSC Label for efavirenz / emtricitabine / tenofovir disoproxil and CYP2B6	HCSC		Informative PGx							efavirenz / emtricitabine / tenofovir disoproxil	CYP2B6		
https://www.pharmgkb.org/labelAnnotation/PA166127661		PA166127661	Annotation of HCSC Label for dexlansoprazole and CYP2C19	HCSC		Informative PGx							dexlansoprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166127659		PA166127659	Annotation of HCSC Label for darifenacin and CYP2D6	HCSC		Informative PGx							darifenacin	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127657		PA166127657	Annotation of HCSC Label for dapsone and G6PD	HCSC		No Clinical PGx							dapsone	G6PD		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166123416		PA166123416	Annotation of EMA Label for ivabradine and CYP3A4	EMA									ivabradine	CYP3A4		8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166129447		PA166129447	Annotation of EMA Label for eliglustat and CYP2D6	EMA		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166127714		PA166127714	Annotation of HCSC Label for sulfadiazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfadiazine	G6PD		7/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127688		PA166127688	Annotation of HCSC Label for lomitapide and LDLR	HCSC									lomitapide	LDLR		12/19/2023
https://www.pharmgkb.org/labelAnnotation/PA166127686		PA166127686	Annotation of HCSC Label for lenalidomide	HCSC		Testing Required					Cancer Genome		lenalidomide			5/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166127684		PA166127684	Annotation of HCSC Label for ivacaftor and CFTR	HCSC		Testing Required							ivacaftor	CFTR	rs113993960; rs121908755; rs121908757; rs121909005; rs121909013; rs121909041; rs193922525; rs267606723; rs397508453; rs74503330; rs75527207; rs80282562	4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127683		PA166127683	Annotation of HCSC Label for irinotecan and UGT1A1	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	irinotecan	UGT1A1	UGT1A1*28; UGT1A1*6	5/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166127696		PA166127696	Annotation of HCSC Label for norfloxacin and G6PD	HCSC		Informative PGx							norfloxacin	G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166127698		PA166127698	Annotation of HCSC Label for omeprazole and CYP2C19	HCSC		No Clinical PGx							omeprazole	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166127694		PA166127694	Annotation of HCSC Label for nitrofurantoin and G6PD	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166127715		PA166127715	Annotation of HCSC Label for sulfamethoxazole / trimethoprim and G6PD	HCSC		Informative PGx							sulfamethoxazole / trimethoprim	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166127690		PA166127690	"Annotation of HCSC Label for mercaptopurine and NUDT15, TPMT"	HCSC		Testing Recommended	Prescribing Info	Dosing Info				Prescribing	mercaptopurine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3C	7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127692		PA166127692	Annotation of HCSC Label for mycophenolic acid and HPRT1	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	mycophenolic acid	HPRT1		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127718		PA166127718	"Annotation of HCSC Label for tamoxifen and ESR1, ESR2, PGR"	HCSC		Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166127716		PA166127716	Annotation of HCSC Label for sulfasalazine and G6PD	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	sulfasalazine	G6PD		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166127697		PA166127697	Annotation of HCSC Label for nortriptyline and CYP2D6	HCSC		Informative PGx							nortriptyline	CYP2D6		7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166123423		PA166123423	Annotation of EMA Label for tipranavir and CYP3A4	EMA									tipranavir	CYP3A4		8/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166129450		PA166129450	Annotation of EMA Label for trametinib and BRAF	EMA		Testing Required					Cancer Genome		trametinib	BRAF		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166129520		PA166129520	"Annotation of HCSC Label for sevoflurane and CACNA1S, RYR1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166182753		PA166182753	Annotation of FDA Label for meloxicam and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	meloxicam	CYP2C9	CYP2C9*3	8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166127719		PA166127719	Annotation of HCSC Label for tetrabenazine and CYP2D6	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tetrabenazine	CYP2D6		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166127720		PA166127720	"Annotation of HCSC Label for thioguanine and NUDT15, TPMT"	HCSC		Testing Recommended	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	thioguanine	NUDT15; TPMT	rs116855232; TPMT*2; TPMT*3A; TPMT*3B; TPMT*3C; TPMT*4	7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166190201		PA166190201	"Annotation of FDA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166189821		PA166189821	Annotation of FDA Label for voxelotor and HBB	FDA	On FDA Biomarker List								voxelotor	HBB		3/31/2024
https://www.pharmgkb.org/labelAnnotation/PA166190741		PA166190741	Annotation of FDA Label for golodirsen and DMD	FDA	On FDA Biomarker List	Testing Required							golodirsen	DMD		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166189982		PA166189982	Annotation of FDA Label for crizanlizumab-tmca and HBB	FDA	On FDA Biomarker List								crizanlizumab-tmca	HBB		3/31/2024
https://www.pharmgkb.org/labelAnnotation/PA166124617		PA166124617	Annotation of FDA Label for ceritinib and ALK	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ceritinib	ALK		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166115367		PA166115367	Annotation of FDA Label for velaglucerase alfa and GBA	FDA	Formerly on FDA Biomarker List								velaglucerase alfa	GBA		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166114910		PA166114910	Annotation of FDA Label for chlorpropamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	chlorpropamide	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166104787		PA166104787	Annotation of FDA Label for cevimeline and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	cevimeline	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166184423		PA166184423	Annotation of Swissmedic Label for antithrombotic agents and G6PD	Swissmedic		Actionable PGx							antithrombotic agents	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184111		PA166184111	Annotation of Swissmedic Label for atomoxetine and CYP2D6	Swissmedic		Actionable PGx							atomoxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184456		PA166184456	Annotation of Swissmedic Label for glyburide and G6PD	Swissmedic		Actionable PGx							glyburide	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184223		PA166184223	"Annotation of Swissmedic Label for Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup) and CYP2D6, G6PD"	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	"Paracetamol, combinations excl. Psycholeptics (Vicks MediNait Sirup)"	CYP2D6; G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184428		PA166184428	Annotation of Swissmedic Label for sertindole and CYP2D6	Swissmedic		Actionable PGx							sertindole	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184231		PA166184231	Annotation of Swissmedic Label for umeclidinium and CYP2D6	Swissmedic		Informative PGx							umeclidinium	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184237		PA166184237	Annotation of Swissmedic Label for Vitamin B-complex with vitamin C and G6PD	Swissmedic		Actionable PGx							Vitamin B-complex with vitamin C	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166184490		PA166184490	Annotation of Swissmedic Label for zuclopenthixol and CYP2D6	Swissmedic									zuclopenthixol	CYP2D6		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166184499		PA166184499	"Annotation of Swissmedic Label for rosuvastatin and ABCG2, SLCO1B1"	Swissmedic		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166184434		PA166184434	"Annotation of Swissmedic Label for sofosbuvir and IFNL3, IFNL4"	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	sofosbuvir	IFNL3; IFNL4	rs12979860	
https://www.pharmgkb.org/labelAnnotation/PA166223861		PA166223861	Annotation of FDA Label for bupropion and CYP2D6	FDA	On FDA Biomarker List								bupropion	CYP2D6		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166223902		PA166223902	Annotation of FDA Label for alglucosidase alfa and GAA	FDA	On FDA Biomarker List	Testing Required							alglucosidase alfa	GAA		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166223941		PA166223941	Annotation of FDA Label for avapritinib and PDGFRA	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166224061		PA166224061	Annotation of HCSC Label for oxcarbazepine and HLA-B	HCSC		Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	oxcarbazepine	HLA-B	HLA-B*15:02	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166127664		PA166127664	Annotation of FDA Label for ibrutinib	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib			8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166224361		PA166224361	Annotation of FDA Label for gemtuzumab ozogamicin and CD33	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166224101		PA166224101	Annotation of FDA Label for citalopram and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							citalopram	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166224962		PA166224962	Annotation of FDA Label for isatuximab	FDA	On FDA Biomarker List						Cancer Genome		isatuximab			8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166224961		PA166224961	Annotation of FDA Label for inebilizumab and AQP4	FDA	On FDA Biomarker List								inebilizumab	AQP4		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166224121		PA166224121	Annotation of FDA Label for escitalopram and CYP2D6	FDA	On FDA Biomarker List								escitalopram	CYP2D6		10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166224441		PA166224441	Annotation of FDA Label for ibrutinib and MYD88	FDA	On FDA Biomarker List						Cancer Genome		ibrutinib	MYD88	rs387907272	8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166224221		PA166224221	"Annotation of FDA Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	FDA	On FDA Biomarker List								eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166225161		PA166225161	Annotation of FDA Label for oliceridine and CYP2D6	FDA		Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	oliceridine	CYP2D6		9/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166185145		PA166185145	Annotation of FDA Label for brentuximab vedotin and TNFRSF8	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	TNFRSF8		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166227321		PA166227321	Annotation of HCSC Label for amifampridine phosphate and NAT2	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2		
https://www.pharmgkb.org/labelAnnotation/PA166227161		PA166227161	Annotation of EMA Label for ramucirumab and KRAS	EMA							Cancer Genome		ramucirumab	KRAS		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166227221		PA166227221	Annotation of EMA Label for amifampridine phosphate and NAT2	EMA		Informative PGx							amifampridine phosphate	NAT2		
https://www.pharmgkb.org/labelAnnotation/PA166160054		PA166160054	Annotation of FDA Label for brexpiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	brexpiprazole	CYP2D6		5/1/2019
https://www.pharmgkb.org/labelAnnotation/PA166227101		PA166227101	Annotation of EMA Label for alglucosidase alfa and GAA	EMA		Testing Required							alglucosidase alfa	GAA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166227121		PA166227121	Annotation of HCSC Label for alglucosidase alfa and GAA	HCSC		Testing Required							alglucosidase alfa	GAA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166227141		PA166227141	Annotation of EMA Label for ramucirumab and EGFR	EMA		Testing Required					Cancer Genome		ramucirumab	EGFR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166227181		PA166227181	"Annotation of EMA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA"	EMA		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166227201		PA166227201	"Annotation of HCSC Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA"	HCSC		Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166234761		PA166234761	Annotation of FDA Label for simvastatin and SLCO1B1	FDA									simvastatin	SLCO1B1		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166235981		PA166235981	Annotation of FDA Label for pralsetinib and RET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pralsetinib	RET	rs74799832; rs77709286	8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166235921		PA166235921	"Annotation of FDA Label for metreleptin and AGPAT2, BSCL2, LEP"	FDA	On FDA Biomarker List	Testing Required							metreleptin	AGPAT2; BSCL2; LEP		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166235361		PA166235361	Annotation of FDA Label for lumasiran and AGXT	FDA	On FDA Biomarker List								lumasiran	AGXT		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166184430		PA166184430	"Annotation of Swissmedic Label for fenofibrate, simvastatin and SLCO1B1"	Swissmedic		Actionable PGx							fenofibrate; simvastatin	SLCO1B1	rs4149056	
https://www.pharmgkb.org/labelAnnotation/PA166184158		PA166184158	"Annotation of Swissmedic Label for ombitasvir / paritaprevir / ritonavir and IFNL3, IFNL4"	Swissmedic		Actionable PGx							ombitasvir / paritaprevir / ritonavir	IFNL3; IFNL4	rs12979860	
https://www.pharmgkb.org/labelAnnotation/PA166184394		PA166184394	"Annotation of Swissmedic Label for prasugrel and CYP2B6, CYP2C19, CYP2C9, CYP3A5"	Swissmedic		Informative PGx							prasugrel	CYP2B6; CYP2C19; CYP2C9; CYP3A5		
https://www.pharmgkb.org/labelAnnotation/PA166127645		PA166127645	"Annotation of HCSC Label for carbamazepine and HLA-A, HLA-B"	HCSC		Testing Recommended							carbamazepine	HLA-A; HLA-B		
https://www.pharmgkb.org/labelAnnotation/PA166160718		PA166160718	"Annotation of PMDA Label for methylene blue and BLVRB, G6PD"	PMDA		Actionable PGx							methylene blue	BLVRB; G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166160274		PA166160274	"Annotation of PMDA Label for cetuximab and EGFR, KRAS"	PMDA		Testing Required							cetuximab	EGFR; KRAS		
https://www.pharmgkb.org/labelAnnotation/PA166160711		PA166160711	"Annotation of PMDA Label for everolimus and ERBB2, ESR1, ESR2"	PMDA		Testing Required							everolimus	ERBB2; ESR1; ESR2		
https://www.pharmgkb.org/labelAnnotation/PA166184426		PA166184426	"Annotation of Swissmedic Label for tolterodine and CYP2D6, CYP3A4"	Swissmedic		Actionable PGx							tolterodine	CYP2D6; CYP3A4		
https://www.pharmgkb.org/labelAnnotation/PA166120287		PA166120287	"Annotation of EMA Label for ethinyl estradiol / norelgestromin and F5, PROC, PROS1, SERPINC1"	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F5; PROC; PROS1; SERPINC1		2/16/2023
https://www.pharmgkb.org/labelAnnotation/PA166163419		PA166163419	"Annotation of FDA Label for rucaparib and BRCA1, BRCA2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		rucaparib	BRCA1; BRCA2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166104915		PA166104915	"Annotation of EMA Label for olanzapine and CYP1A2, CYP2D6"	EMA									olanzapine	CYP1A2; CYP2D6		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166104817		PA166104817	"Annotation of FDA Label for tretinoin and PML, RARA"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tretinoin	PML; RARA		9/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166104819		PA166104819	"Annotation of FDA Label for tamoxifen and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tamoxifen	ESR1; ESR2; PGR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104907		PA166104907	"Annotation of EMA Label for eltrombopag and F5, SERPINC1"	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166170938		PA166170938	"Annotation of FDA Label for trametinib and HRAS, KRAS, NRAS"	FDA	On FDA Biomarker List						Cancer Genome		trametinib	HRAS; KRAS; NRAS		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166184560		PA166184560	"Annotation of FDA Label for ramucirumab and ALK, EGFR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		ramucirumab	ALK; EGFR		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166104909		PA166104909	"Annotation of EMA Label for crizotinib and ALK, ROS1"	EMA		Testing Required					Cancer Genome		crizotinib	ALK; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104821		PA166104821	"Annotation of EMA Label for arsenic trioxide and PML, RARA"	EMA		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166127632		PA166127632	"Annotation of HCSC Label for arsenic trioxide and PML, RARA"	HCSC		Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166127648		PA166127648	"Annotation of HCSC Label for cetuximab and EGFR, KRAS"	HCSC		Testing Required					Cancer Genome		cetuximab	EGFR; KRAS		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127699		PA166127699	"Annotation of HCSC Label for panitumumab and KRAS, NRAS"	HCSC		Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		8/12/2024
https://www.pharmgkb.org/labelAnnotation/PA166104911		PA166104911	"Annotation of EMA Label for everolimus and ERBB2, ESR1, ESR2"	EMA		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104919		PA166104919	"Annotation of EMA Label for fulvestrant and ERBB2, ESR1, ESR2, PGR"	EMA		Testing Required					Cancer Genome		fulvestrant	ERBB2; ESR1; ESR2; PGR		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166104926		PA166104926	"Annotation of EMA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB"	EMA		Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166104809		PA166104809	"Annotation of FDA Label for panitumumab and KRAS, NRAS"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		panitumumab	KRAS; NRAS		8/12/2024
https://www.pharmgkb.org/labelAnnotation/PA166120370		PA166120370	"Annotation of EMA Label for glimepiride, pioglitazone and G6PD"	EMA		Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride; pioglitazone	G6PD		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166104914		PA166104914	"Annotation of EMA Label for dasatinib and ABL1, BCR"	EMA		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166182923		PA166182923	"Annotation of EMA Label for abemaciclib and ERBB2, ESR1, ESR2, PGR"	EMA		Testing Required					Cancer Genome		abemaciclib	ERBB2; ESR1; ESR2; PGR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104823		PA166104823	"Annotation of EMA Label for methylene blue and BLVRB, CYB5R3, G6PD"	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	BLVRB; CYB5R3; G6PD		2/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166184224		PA166184224	"Annotation of Swissmedic Label for acetaminophen, acetaminophen / tramadol and G6PD"	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	acetaminophen; acetaminophen / tramadol	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166123527		PA166123527	"Annotation of PMDA Label for arsenic trioxide and PML, RARA"	PMDA		Testing Required							arsenic trioxide	PML; RARA		
https://www.pharmgkb.org/labelAnnotation/PA166123532		PA166123532	"Annotation of PMDA Label for carbamazepine and HLA-A, HLA-B"	PMDA		Actionable PGx							carbamazepine	HLA-A; HLA-B		
https://www.pharmgkb.org/labelAnnotation/PA166123540		PA166123540	"Annotation of PMDA Label for fulvestrant and ESR1, ESR2"	PMDA		Testing Required							fulvestrant	ESR1; ESR2		
https://www.pharmgkb.org/labelAnnotation/PA166123541		PA166123541	"Annotation of PMDA Label for gefitinib and CYP2D6, EGFR"	PMDA		Testing Required							gefitinib	CYP2D6; EGFR		
https://www.pharmgkb.org/labelAnnotation/PA166123542		PA166123542	"Annotation of PMDA Label for imatinib and ABL1, BCR"	PMDA		Testing Required							imatinib	ABL1; BCR		
https://www.pharmgkb.org/labelAnnotation/PA166123544		PA166123544	"Annotation of PMDA Label for lapatinib and ERBB2, HLA-DQA1, HLA-DRB1"	PMDA		Testing Required							lapatinib	ERBB2; HLA-DQA1; HLA-DRB1		
https://www.pharmgkb.org/labelAnnotation/PA166123552		PA166123552	"Annotation of PMDA Label for valproic acid and CPS1, OTC"	PMDA		Actionable PGx							valproic acid	CPS1; OTC		
https://www.pharmgkb.org/labelAnnotation/PA166127672		PA166127672	"Annotation of HCSC Label for exemestane and ESR1, ESR2"	HCSC		Testing Required							exemestane	ESR1; ESR2		
https://www.pharmgkb.org/labelAnnotation/PA166183781		PA166183781	"Annotation of Swissmedic Label for mercaptopurine and NUDT15, TPMT"	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	mercaptopurine	NUDT15; TPMT	TPMT*2; TPMT*3A; TPMT*3C	
https://www.pharmgkb.org/labelAnnotation/PA166127668		PA166127668	"Annotation of HCSC Label for eltrombopag and F5, SERPINC1"	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	eltrombopag	F5; SERPINC1	rs6025	7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166185190		PA166185190	"Annotation of FDA Label for ospemifene and CYP2B6, CYP2C9"	FDA	On FDA Biomarker List								ospemifene	CYP2B6; CYP2C9		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166127666		PA166127666	"Annotation of HCSC Label for drospirenone / ethinyl estradiol and F5, PROC, PROS1, SERPINC1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	drospirenone / ethinyl estradiol	F5; PROC; PROS1; SERPINC1	rs6025	7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166127726		PA166127726	"Annotation of HCSC Label for valproic acid and OTC, POLG"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	valproic acid	OTC; POLG		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166127685		PA166127685	Annotation of HCSC Label for lapatinib and ERBB2	HCSC		Testing Required					Cancer Genome		lapatinib	ERBB2		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166236241		PA166236241	"Annotation of FDA Label for satralizumab and AQP4, IL6R"	FDA	On FDA Biomarker List								satralizumab	AQP4; IL6R		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166182759		PA166182759	"Annotation of FDA Label for chloroprocaine and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	chloroprocaine	CYB5R3; G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166129517		PA166129517	"Annotation of FDA Label for isoflurane and CACNA1S, RYR1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	isoflurane	CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166235941		PA166235941	"Annotation of FDA Label for setmelanotide and LEPR, PCSK1, POMC"	FDA	On FDA Biomarker List	Testing Required							setmelanotide	LEPR; PCSK1; POMC		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166123410		PA166123410	"Annotation of EMA Label for ritonavir and CYP2D6, CYP3A4"	EMA									ritonavir	CYP2D6; CYP3A4		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166123551		PA166123551	"Annotation of PMDA Label for tretinoin and PML, RARA"	PMDA							Cancer Genome		tretinoin	PML; RARA		9/26/2023
https://www.pharmgkb.org/labelAnnotation/PA166105232		PA166105232	"Annotation of FDA Label for quinine and CYP2D6, G6PD"	FDA	On FDA Biomarker List								quinine	CYP2D6; G6PD		4/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166127671		PA166127671	"Annotation of HCSC Label for everolimus and ERBB2, ESR1, ESR2"	HCSC		Testing Required					Cancer Genome		everolimus	ERBB2; ESR1; ESR2		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127682		PA166127682	"Annotation of HCSC Label for imatinib and ABI1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB"	HCSC		Testing Required					Cancer Genome		imatinib	ABI1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166104840		PA166104840	"Annotation of EMA Label for lapatinib and ERBB2, ESR1, ESR2"	EMA		Testing Required					Cancer Genome		lapatinib	ERBB2; ESR1; ESR2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166105334		PA166105334	"Annotation of EMA Label for nilotinib and ABL1, BCR"	EMA		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183421		PA166183421	"Annotation of EMA Label for ribociclib and ERBB2, ESR1, ESR2, PGR"	EMA		Testing Required					Cancer Genome		ribociclib	ERBB2; ESR1; ESR2; PGR		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183425		PA166183425	"Annotation of EMA Label for talazoparib and BRCA1, BRCA2, ERBB2"	EMA		Testing Required					Cancer Genome		talazoparib	BRCA1; BRCA2; ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127695		PA166127695	"Annotation of HCSC Label for ethinyl estradiol / norelgestromin and F2, F5, MTHFR, PROC, PROS1, SERPINC1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	ethinyl estradiol / norelgestromin	F2; F5; MTHFR; PROC; PROS1; SERPINC1	rs1799963; rs1801131; rs1801133	7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127687		PA166127687	"Annotation of HCSC Label for letrozole and ESR1, ESR2, PGR"	HCSC		Testing Required					Cancer Genome		letrozole	ESR1; ESR2; PGR		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166127693		PA166127693	"Annotation of HCSC Label for nilotinib and ABL1, BCR"	HCSC		Testing Required					Cancer Genome		nilotinib	ABL1; BCR		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166127712		PA166127712	"Annotation of HCSC Label for sodium phenylbutyrate and ASS1, CPS1, OTC"	HCSC									sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166114381		PA166114381	"Annotation of EMA Label for sodium phenylbutyrate and ASS1, CPS1, OTC"	EMA									sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166182789		PA166182789	"Annotation of EMA Label for toremifene and ESR1, ESR2"	EMA							Cancer Genome		toremifene	ESR1; ESR2		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127660		PA166127660	"Annotation of HCSC Label for dasatinib and ABL1, BCR"	HCSC		Testing Required					Cancer Genome		dasatinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166240301		PA166240301	"Annotation of EMA Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1"	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166246485		PA166246485	Annotation of FDA Label for sotorasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sotorasib	KRAS	rs121913530	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166248801		PA166248801	Annotation of FDA Label for anakinra and IL1RN	FDA									anakinra	IL1RN		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166252901		PA166252901	"Annotation of FDA Label for tepotinib and ALK, EGFR"	FDA	On FDA Biomarker List						Cancer Genome		tepotinib	ALK; EGFR		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166251482		PA166251482	Annotation of FDA Label for dostarlimab	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dostarlimab			8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166252881		PA166252881	Annotation of FDA Label for tepotinib and MET	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		tepotinib	MET		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166252081		PA166252081	Annotation of FDA Label for infigratinib and FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		infigratinib	FGFR2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166251821		PA166251821	Annotation of FDA Label for evinacumab and LDLR	FDA	On FDA Biomarker List								evinacumab	LDLR		8/20/2024
https://www.pharmgkb.org/labelAnnotation/PA166269081		PA166269081	Annotation of FDA Label for glycerol phenylbutyrate and NAGS	FDA	On FDA Biomarker List								glycerol phenylbutyrate	NAGS		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166269121		PA166269121	Annotation of FDA Label for nateglinide and CYP2C9	FDA	On FDA Biomarker List	Informative PGx							nateglinide	CYP2C9		8/28/2024
https://www.pharmgkb.org/labelAnnotation/PA166268901		PA166268901	"Annotation of FDA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	FDA	On FDA Biomarker List								efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166268923		PA166268923	Annotation of FDA Label for ropeginterferon alfa-2b and JAK2	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	7/6/2022
https://www.pharmgkb.org/labelAnnotation/PA166170052		PA166170052	Annotation of FDA Label for valbenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	valbenazine	CYP2D6		4/12/2022
https://www.pharmgkb.org/labelAnnotation/PA166269101		PA166269101	"Annotation of FDA Label for glycerol phenylbutyrate and ASS1, CPS1, OTC"	FDA	On FDA Biomarker List	Testing Required							glycerol phenylbutyrate	ASS1; CPS1; OTC		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166179878		PA166179878	Annotation of FDA Label for encorafenib and BRAF	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	10/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166268902		PA166268902	"Annotation of FDA Label for odevixibat and ABCB11, ATP8B1"	FDA	On FDA Biomarker List								odevixibat	ABCB11; ATP8B1	rs11568372; rs72549402	8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166234701		PA166234701	Annotation of FDA Label for allopurinol and HLA-B	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	allopurinol	HLA-B	HLA-B*58:01	5/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166122592		PA166122592	Annotation of FDA Label for simeprevir and IFNL3	FDA	On FDA Biomarker List	Informative PGx							simeprevir	IFNL3	rs12979860	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166127710		PA166127710	Annotation of HCSC Label for simeprevir and IFNL3	HCSC		Informative PGx							simeprevir	IFNL3	rs12979860	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166122607		PA166122607	Annotation of FDA Label for vortioxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	vortioxetine	CYP2D6		8/10/2023
https://www.pharmgkb.org/labelAnnotation/PA166182741		PA166182741	"Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	articaine / epinephrine	CYB5R3; G6PD		10/24/2019
https://www.pharmgkb.org/labelAnnotation/PA166170929		PA166170929	Annotation of FDA Label for gefitinib and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	gefitinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104780		PA166104780	Annotation of FDA Label for carbamazepine and HLA-B	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	carbamazepine	HLA-B	HLA-B*15:02	4/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166104807		PA166104807	Annotation of FDA Label for fluorouracil and DPYD	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info		Alternate Drug			Prescribing	fluorouracil	DPYD		4/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166246301		PA166246301	Annotation of FDA Label for acetaminophen / caffeine / dihydrocodeine and CYP2D6	FDA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	acetaminophen / caffeine / dihydrocodeine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104839		PA166104839	Annotation of FDA Label for aripiprazole and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	aripiprazole	CYP2D6		5/9/2019
https://www.pharmgkb.org/labelAnnotation/PA166104838		PA166104838	"Annotation of FDA Label for thioguanine and NUDT15, TPMT"	FDA	On FDA Biomarker List	Testing Recommended	Prescribing Info	Dosing Info				Prescribing	thioguanine	NUDT15; TPMT		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166104801		PA166104801	Annotation of FDA Label for peginterferon alfa-2b and IFNL3	FDA	On FDA Biomarker List	Informative PGx							peginterferon alfa-2b	IFNL3	rs12979860	4/19/2019
https://www.pharmgkb.org/labelAnnotation/PA166278361		PA166278361	Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6	FDA		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	dextromethorphan hydrobromide / bupropion hydrochloride	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166170935		PA166170935	"Annotation of FDA Label for rucaparib and CYP1A2, CYP2D6"	FDA	On FDA Biomarker List	No Clinical PGx							rucaparib	CYP1A2; CYP2D6		10/28/2020
https://www.pharmgkb.org/labelAnnotation/PA166178750		PA166178750	Annotation of FDA Label for metoclopramide and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166179887		PA166179887	Annotation of FDA Label for raltegravir and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							raltegravir	UGT1A1	UGT1A1*28	4/23/2019
https://www.pharmgkb.org/labelAnnotation/PA166129519		PA166129519	"Annotation of FDA Label for sevoflurane and CACNA1S, RYR1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	sevoflurane	CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166104829		PA166104829	Annotation of FDA Label for tetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info				Prescribing	tetrabenazine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166293341		PA166293341	"Annotation of FDA Label for tremelimumab and ALK, EGFR"	FDA	On FDA Biomarker List						Cancer Genome		tremelimumab	ALK; EGFR		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166104827		PA166104827	Annotation of FDA Label for atomoxetine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	atomoxetine	CYP2D6		5/9/2019
https://www.pharmgkb.org/labelAnnotation/PA166104856		PA166104856	Annotation of FDA Label for amitriptyline and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amitriptyline	CYP2D6		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166104874		PA166104874	"Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD, NAT2"	FDA	On FDA Biomarker List	Informative PGx							sulfamethoxazole / trimethoprim	G6PD; NAT2		10/10/2019
https://www.pharmgkb.org/labelAnnotation/PA166268861		PA166268861	"Annotation of FDA Label for asciminib and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info			Cancer Genome	Prescribing	asciminib	ABL1; BCR	rs121913459	10/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166273021		PA166273021	Annotation of FDA Label for mavacamten and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							mavacamten	CYP2C19	CYP2C19*2; CYP2C19*3	12/20/2023
https://www.pharmgkb.org/labelAnnotation/PA166104879		PA166104879	Annotation of FDA Label for imipramine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							imipramine	CYP2D6		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166104885		PA166104885	Annotation of FDA Label for norfloxacin and G6PD	FDA		Informative PGx							norfloxacin	G6PD		4/14/2019
https://www.pharmgkb.org/labelAnnotation/PA166104895		PA166104895	Annotation of FDA Label for erythromycin ethylsuccinate / sulfisoxazole acetyl and G6PD	FDA	On FDA Biomarker List	Informative PGx							erythromycin ethylsuccinate / sulfisoxazole acetyl	G6PD		7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166104795		PA166104795	"Annotation of FDA Label for busulfan and ABL1, BCR"	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		busulfan	ABL1; BCR		2/3/2024
https://www.pharmgkb.org/labelAnnotation/PA166114926		PA166114926	Annotation of FDA Label for mafenide and G6PD	FDA	On FDA Biomarker List	Informative PGx							mafenide	G6PD		7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166104878		PA166104878	Annotation of FDA Label for methylene blue and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	methylene blue	G6PD		12/17/2013
https://www.pharmgkb.org/labelAnnotation/PA166160007		PA166160007	Annotation of FDA Label for lesinurad and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lesinurad	CYP2C9		
https://www.pharmgkb.org/labelAnnotation/PA166105058		PA166105058	"Annotation of FDA Label for pazopanib and HLA-B, UGT1A1"	FDA	On FDA Biomarker List	Informative PGx							pazopanib	HLA-B; UGT1A1	HLA-B*57:01; UGT1A1*28	4/19/2019
https://www.pharmgkb.org/labelAnnotation/PA166122972		PA166122972	Annotation of FDA Label for fesoterodine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							fesoterodine	CYP2D6		3/15/2017
https://www.pharmgkb.org/labelAnnotation/PA166122971		PA166122971	Annotation of FDA Label for darifenacin and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							darifenacin	CYP2D6		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166182728		PA166182728	"Annotation of FDA Label for ropivacaine and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Informative PGx							ropivacaine	CYB5R3; G6PD		10/17/2019
https://www.pharmgkb.org/labelAnnotation/PA166160052		PA166160052	Annotation of FDA Label for palonosetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							palonosetron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166105195		PA166105195	"Annotation of FDA Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD"	FDA	On FDA Biomarker List	Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD		10/17/2019
https://www.pharmgkb.org/labelAnnotation/PA166170933		PA166170933	"Annotation of FDA Label for pertuzumab and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Informative PGx					Cancer Genome		pertuzumab	ESR1; ESR2; PGR		4/19/2019
https://www.pharmgkb.org/labelAnnotation/PA166182749		PA166182749	"Annotation of FDA Label for lusutrombopag and F2, F5, PROC, PROS1, SERPINC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lusutrombopag	F2; F5; PROC; PROS1; SERPINC1	rs1799963; rs6025	7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166182737		PA166182737	Annotation of FDA Label for lidocaine and tetracaine and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lidocaine and tetracaine	G6PD		10/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166161219		PA166161219	Annotation of FDA Label for aripiprazole lauroxil and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	aripiprazole lauroxil	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104837		PA166104837	Annotation of FDA Label for propafenone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							propafenone	CYP2D6		7/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166177514		PA166177514	Annotation of FDA Label for mirabegron and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							mirabegron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104903		PA166104903	Annotation of FDA Label for nitrofurantoin and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	nitrofurantoin	G6PD		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166160672		PA166160672	Annotation of FDA Label for tamsulosin and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	tamsulosin	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166105117		PA166105117	Annotation of FDA Label for efavirenz and CYP2B6	FDA	On FDA Biomarker List	Informative PGx							efavirenz	CYP2B6	CYP2B6*6	7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166177521		PA166177521	Annotation of FDA Label for umeclidinium and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							umeclidinium	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166182747		PA166182747	Annotation of FDA Label for lorlatinib and ROS1	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		lorlatinib	ROS1		7/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166169912		PA166169912	Annotation of FDA Label for enflurane	FDA	Formerly on FDA Biomarker List								enflurane			11/30/2023
https://www.pharmgkb.org/labelAnnotation/PA166104847		PA166104847	Annotation of FDA Label for venlafaxine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							venlafaxine	CYP2D6		10/25/2013
https://www.pharmgkb.org/labelAnnotation/PA166185156		PA166185156	Annotation of FDA Label for mivacurium and BCHE	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	mivacurium	BCHE		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166182746		PA166182746	"Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	ceftriaxone	CYB5R3; G6PD		10/24/2019
https://www.pharmgkb.org/labelAnnotation/PA166151882		PA166151882	Annotation of FDA Label for carbamazepine and HLA-A	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	carbamazepine	HLA-A	HLA-A*31:01	10/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166185151		PA166185151	Annotation of FDA Label for amifampridine and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine	NAT2		5/10/2024
https://www.pharmgkb.org/labelAnnotation/PA166170934		PA166170934	"Annotation of FDA Label for primaquine and CYB5R1, CYB5R2, CYB5R3, CYB5R4"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	primaquine	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166160049		PA166160049	Annotation of FDA Label for lacosamide and CYP2C19	FDA	On FDA Biomarker List	No Clinical PGx							lacosamide	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166122970		PA166122970	"Annotation of FDA Label for succinylcholine and BCHE, CACNA1S, RYR1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166224341		PA166224341	"Annotation of FDA Label for encorafenib and HRAS, KRAS, NRAS"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug		Cancer Genome	Prescribing	encorafenib	HRAS; KRAS; NRAS		8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166104897		PA166104897	Annotation of FDA Label for moviprep and G6PD	FDA	Formerly on FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	moviprep	G6PD		12/18/2013
https://www.pharmgkb.org/labelAnnotation/PA166105211		PA166105211	Annotation of FDA Label for ondansetron and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							ondansetron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166115362		PA166115362	"Annotation of FDA Label for sodium nitrite and CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	sodium nitrite	CYB5R3; G6PD		10/16/2019
https://www.pharmgkb.org/labelAnnotation/PA166179848		PA166179848	Annotation of FDA Label for lofexidine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	lofexidine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166105147		PA166105147	Annotation of FDA Label for glimepiride and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glimepiride	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166184637		PA166184637	"Annotation of FDA Label for oxymetazoline and tetracaine and BCHE, CYB5R3, G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	oxymetazoline and tetracaine	BCHE; CYB5R3; G6PD		10/24/2019
https://www.pharmgkb.org/labelAnnotation/PA166104852		PA166104852	Annotation of FDA Label for citalopram and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	citalopram	CYP2C19		9/22/2020
https://www.pharmgkb.org/labelAnnotation/PA166278181		PA166278181	"Annotation of FDA Label for azacitidine and CBL, KRAS, NRAS, PTPN11"	FDA	On FDA Biomarker List						Cancer Genome		azacitidine	CBL; KRAS; NRAS; PTPN11		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166293201		PA166293201	Annotation of FDA Label for capecitabine and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capecitabine	ERBB2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166277661		PA166277661	Annotation of FDA Label for vutrisiran and TTR	FDA	On FDA Biomarker List								vutrisiran	TTR		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166104790		PA166104790	"Annotation of FDA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		imatinib	ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166273561		PA166273561	"Annotation of FDA Label for inclisiran and APOB, LDLR, PCSK9"	FDA	On FDA Biomarker List								inclisiran	APOB; LDLR; PCSK9		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166104860		PA166104860	"Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	phenytoin	CYP2C19; CYP2C9; HLA-B	CYP2C9*2; CYP2C9*3; HLA-B*15:02	8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166278081		PA166278081	Annotation of FDA Label for mitapivat and PKLR	FDA	On FDA Biomarker List								mitapivat	PKLR		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166296341		PA166296341	"Annotation of FDA Label for pemetrexed and ALK, EGFR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		pemetrexed	ALK; EGFR		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166251421		PA166251421	"Annotation of FDA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166278161		PA166278161	Annotation of FDA Label for lutetium (177lu) vipivotide tetraxetan and FOLH1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177lu) vipivotide tetraxetan	FOLH1		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166296361		PA166296361	Annotation of FDA Label for pemetrexed and CD274	FDA	On FDA Biomarker List						Cancer Genome		pemetrexed	CD274		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166277841		PA166277841	Annotation of FDA Label for sacrosidase and SI	FDA	On FDA Biomarker List	Testing Required							sacrosidase	SI		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166104846		PA166104846	"Annotation of FDA Label for arsenic trioxide and PML, RARA"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		arsenic trioxide	PML; RARA		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166234723		PA166234723	Annotation of FDA Label for atorvastatin and SLCO1B1	FDA									atorvastatin	SLCO1B1		12/4/2023
https://www.pharmgkb.org/labelAnnotation/PA166234801		PA166234801	"Annotation of FDA Label for tacrolimus and CYP3A4, CYP3A5"	FDA									tacrolimus	CYP3A4; CYP3A5		8/29/2024
https://www.pharmgkb.org/labelAnnotation/PA166272961		PA166272961	Annotation of FDA Label for abrocitinib and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	abrocitinib	CYP2C19		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166278121		PA166278121	"Annotation of FDA Label for nivolumab / relatlimab and BRAF, CD274, LAG3"	FDA	On FDA Biomarker List						Cancer Genome		nivolumab / relatlimab	BRAF; CD274; LAG3		8/16/2023
https://www.pharmgkb.org/labelAnnotation/PA166179871		PA166179871	Annotation of FDA Label for binimetinib and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							binimetinib	UGT1A1		10/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166277681		PA166277681	Annotation of FDA Label for anifrolumab and IFNAR1	FDA	On FDA Biomarker List								anifrolumab	IFNAR1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166293262		PA166293262	Annotation of FDA Label for adagrasib and KRAS	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		adagrasib	KRAS	rs121913530	9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166252781		PA166252781	Annotation of FDA Label for fosdenopterin and MOCS1	FDA	On FDA Biomarker List	Testing Required							fosdenopterin	MOCS1		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166293401		PA166293401	Annotation of FDA Label for futibatinib and FGFR2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		futibatinib	FGFR2		10/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166182786		PA166182786	Annotation of FDA Label for tolazamide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	tolazamide	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166184561		PA166184561	Annotation of FDA Label for ramucirumab and KRAS	FDA	On FDA Biomarker List						Cancer Genome		ramucirumab	KRAS		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166268881		PA166268881	Annotation of FDA Label for belzutifan and VHL	FDA	On FDA Biomarker List								belzutifan	VHL		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166170958		PA166170958	Annotation of FDA Label for valproic acid and POLG	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	valproic acid	POLG		8/22/2023
https://www.pharmgkb.org/labelAnnotation/PA166169880		PA166169880	Annotation of FDA Label for cerliponase alfa and TPP1	FDA	On FDA Biomarker List								cerliponase alfa	TPP1		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166236221		PA166236221	"Annotation of FDA Label for risdiplam and SMN1, SMN2"	FDA	On FDA Biomarker List	Testing Required							risdiplam	SMN1; SMN2		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166184565		PA166184565	Annotation of FDA Label for tafamidis and TTR	FDA	On FDA Biomarker List								tafamidis	TTR		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166182755		PA166182755	"Annotation of FDA Label for vincristine and ABL1, BCR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		vincristine	ABL1; BCR		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166104923		PA166104923	"Annotation of FDA Label for exemestane and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		exemestane	ESR1; ESR2; PGR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166268941		PA166268941	Annotation of FDA Label for mobocertinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		mobocertinib	EGFR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166159963		PA166159963	"Annotation of FDA Label for blinatumomab and ABL1, BCR, CD19"	FDA	On FDA Biomarker List						Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166127662		PA166127662	"Annotation of FDA Label for arformoterol and CYP2D6, UGT1A1"	FDA	On FDA Biomarker List	No Clinical PGx							arformoterol	CYP2D6; UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166105010		PA166105010	Annotation of FDA Label for duloxetine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							duloxetine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166268961		PA166268961	"Annotation of FDA Label for zanubrutinib and MYD88, TP53"	FDA	On FDA Biomarker List						Cancer Genome		zanubrutinib	MYD88; TP53	rs387907272	10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166177518		PA166177518	Annotation of FDA Label for sofosbuvir / velpatasvir / voxilaprevir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir / velpatasvir / voxilaprevir	IFNL3		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166190643		PA166190643	Annotation of FDA Label for trastuzumab deruxtecan and ERBB2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166182762		PA166182762	Annotation of FDA Label for elagolix and SLCO1B1	FDA	On FDA Biomarker List	Informative PGx							elagolix	SLCO1B1	rs4149056	7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166104792		PA166104792	"Annotation of FDA Label for fulvestrant and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		fulvestrant	ESR1; ESR2; PGR		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166163439		PA166163439	Annotation of FDA Label for elbasvir / grazoprevir and IFNL3	FDA	On FDA Biomarker List								elbasvir / grazoprevir	IFNL3		9/6/2023
https://www.pharmgkb.org/labelAnnotation/PA166160005		PA166160005	Annotation of FDA Label for dasabuvir / ombitasvir / paritaprevir / ritonavir and IFNL3	FDA	On FDA Biomarker List								dasabuvir / ombitasvir / paritaprevir / ritonavir	IFNL3		9/6/2023
https://www.pharmgkb.org/labelAnnotation/PA166251501		PA166251501	Annotation of FDA Label for cabotegravir / rilpivirine and UGT1A1	FDA	On FDA Biomarker List	No Clinical PGx							cabotegravir / rilpivirine	UGT1A1		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166122589		PA166122589	Annotation of FDA Label for afutuzumab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		afutuzumab	MS4A1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166105012		PA166105012	Annotation of FDA Label for escitalopram and CYP2C19	FDA	On FDA Biomarker List	Informative PGx							escitalopram	CYP2C19		10/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166178724		PA166178724	"Annotation of FDA Label for neratinib and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		neratinib	ESR1; ESR2; PGR		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166182764		PA166182764	"Annotation of FDA Label for emapalumab and PRF1, RAB27A, SH2D1A, STX11, STXBP2, UNC13D, XIAP"	FDA	On FDA Biomarker List								emapalumab	PRF1; RAB27A; SH2D1A; STX11; STXBP2; UNC13D; XIAP		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166105070		PA166105070	"Annotation of FDA Label for anastrozole and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		anastrozole	ESR1; ESR2; PGR		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166163431		PA166163431	"Annotation of FDA Label for isosorbide mononitrate and CYB5R1, CYB5R2, CYB5R3, CYB5R4"	FDA	On FDA Biomarker List	Informative PGx							isosorbide mononitrate	CYB5R1; CYB5R2; CYB5R3; CYB5R4		7/30/2024
https://www.pharmgkb.org/labelAnnotation/PA166182742		PA166182742	"Annotation of FDA Label for talazoparib and ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C"	FDA	On FDA Biomarker List	Testing Required							talazoparib	ATM; ATR; BRCA1; BRCA2; CDK12; CHEK2; FANCA; MLH1; MRE11; NBN; PALB2; RAD51C		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166182738		PA166182738	Annotation of FDA Label for siponimod and CYP2C9	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*2; CYP2C9*3	3/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166160056		PA166160056	"Annotation of FDA Label for cholic acid and AKR1D1, AMACR, CYP27A1, CYP7A1, DHCR7, HSD3B2"	FDA	On FDA Biomarker List								cholic acid	AKR1D1; AMACR; CYP27A1; CYP7A1; DHCR7; HSD3B2		8/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166182730		PA166182730	Annotation of FDA Label for amphetamine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							amphetamine	CYP2D6		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166184539		PA166184539	Annotation of FDA Label for paliperidone and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							paliperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166104778		PA166104778	Annotation of FDA Label for brentuximab vedotin and ALK	FDA	On FDA Biomarker List						Cancer Genome		brentuximab vedotin	ALK		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166225001		PA166225001	"Annotation of FDA Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166114923		PA166114923	Annotation of FDA Label for lomitapide	FDA	On FDA Biomarker List								lomitapide			9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166114317		PA166114317	"Annotation of FDA Label for sodium phenylbutyrate and ASS1, CPS1, OTC"	FDA	On FDA Biomarker List								sodium phenylbutyrate	ASS1; CPS1; OTC		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166293701		PA166293701	"Annotation of FDA Label for levothyroxine and IRS4, NKX2-5, PAX8, TBL1X, TSHB"	FDA	On FDA Biomarker List								levothyroxine	IRS4; NKX2-5; PAX8; TBL1X; TSHB		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166169882		PA166169882	Annotation of FDA Label for deutetrabenazine and CYP2D6	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	deutetrabenazine	CYP2D6		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166169918		PA166169918	Annotation of FDA Label for midostaurin and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		midostaurin	FLT3		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166104900		PA166104900	Annotation of FDA Label for pegloticase and G6PD	FDA	On FDA Biomarker List	Testing Required	Prescribing Info		Alternate Drug			Prescribing	pegloticase	G6PD		3/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166182961		PA166182961	Annotation of FDA Label for duvelisib	FDA	On FDA Biomarker List						Cancer Genome		duvelisib			8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166184636		PA166184636	"Annotation of FDA Label for tipiracil / trifluridine and ERBB2, KRAS"	FDA	On FDA Biomarker List						Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166163414		PA166163414	"Annotation of FDA Label for ustekinumab and IL12A, IL12B, IL23A"	FDA	On FDA Biomarker List								ustekinumab	IL12A; IL12B; IL23A		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166177486		PA166177486	Annotation of FDA Label for enasidenib and IDH2	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		enasidenib	IDH2		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166123487		PA166123487	Annotation of FDA Label for eliglustat and CYP2D6	FDA	On FDA Biomarker List	Testing Required	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	eliglustat	CYP2D6		8/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166177483		PA166177483	Annotation of FDA Label for desvenlafaxine and CYP2D6	FDA	On FDA Biomarker List	No Clinical PGx							desvenlafaxine	CYP2D6		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166151878		PA166151878	"Annotation of FDA Label for lapatinib and HLA-DQA1, HLA-DRB1"	FDA	On FDA Biomarker List	Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	8/24/2020
https://www.pharmgkb.org/labelAnnotation/PA166160040		PA166160040	Annotation of FDA Label for Parathyroid Hormones And Analogues and CASR	FDA	On FDA Biomarker List								Parathyroid Hormones And Analogues	CASR		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166122594		PA166122594	Annotation of FDA Label for sofosbuvir and IFNL3	FDA	On FDA Biomarker List								sofosbuvir	IFNL3	rs12979860	8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166182280		PA166182280	Annotation of FDA Label for dacomitinib and EGFR	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		dacomitinib	EGFR	rs121434568	8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166179847		PA166179847	Annotation of FDA Label for ivacaftor / tezacaftor and CFTR	FDA	On FDA Biomarker List	Testing Required							ivacaftor / tezacaftor	CFTR	rs113993958; rs113993960; rs115545701; rs11971167; rs121908752; rs121908753; rs121909020; rs141033578; rs150212784; rs186045772; rs202179988; rs368505753; rs397508256; rs397508288; rs397508387; rs397508442; rs397508513; rs397508537; rs397508759; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs77932196	10/6/2023
https://www.pharmgkb.org/labelAnnotation/PA166105148		PA166105148	Annotation of FDA Label for glipizide and G6PD	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug	Other Prescribing Guidance		Prescribing	glipizide	G6PD		8/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166105113		PA166105113	Annotation of FDA Label for donepezil and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							donepezil	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166182021		PA166182021	Annotation of FDA Label for amifampridine phosphate and NAT2	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info				Prescribing	amifampridine phosphate	NAT2		10/4/2019
https://www.pharmgkb.org/labelAnnotation/PA166170939		PA166170939	"Annotation of FDA Label for trastuzumab and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		trastuzumab	ESR1; ESR2; PGR		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166191561		PA166191561	"Annotation of FDA Label for nivolumab and ALK, CD274, EGFR"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166160133		PA166160133	"Annotation of FDA Label for palbociclib and ERBB2, ESR1, ESR2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		palbociclib	ERBB2; ESR1; ESR2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166313381		PA166313381	"Annotation of FDA Label for polatuzumab vedotin and BCL2, BCL6, MYC"	FDA	On FDA Biomarker List						Cancer Genome		polatuzumab vedotin	BCL2; BCL6; MYC		
https://www.pharmgkb.org/labelAnnotation/PA166114930		PA166114930	"Annotation of FDA Label for omacetaxine and ABL1, BCR"	FDA	On FDA Biomarker List						Cancer Genome		omacetaxine	ABL1; BCR		8/12/2024
https://www.pharmgkb.org/labelAnnotation/PA166314003		PA166314003	"Annotation of FDA Label for odevixibat and JAG1, NOTCH2"	FDA	On FDA Biomarker List								odevixibat	JAG1; NOTCH2		
https://www.pharmgkb.org/labelAnnotation/PA166313361		PA166313361	"Annotation of FDA Label for elacestrant and ERBB2, ESR1"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		elacestrant	ERBB2; ESR1		9/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166159962		PA166159962	Annotation of FDA Label for alirocumab and LDLR	FDA	Formerly on FDA Biomarker List								alirocumab	LDLR		2/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166114921		PA166114921	Annotation of FDA Label for ibritumomab and MS4A1	FDA	Formerly on FDA Biomarker List						Cancer Genome		ibritumomab	MS4A1		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166281101		PA166281101	"Annotation of HCSC Label for eculizumab and AQP4, CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	HCSC									eculizumab	AQP4; CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166281121		PA166281121	"Annotation of EMA Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	EMA									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166273541		PA166273541	Annotation of EMA Label for inebilizumab and AQP4	EMA									inebilizumab	AQP4		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166272761		PA166272761	Annotation of EMA Label for satralizumab and AQP4	EMA									satralizumab	AQP4		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166272123		PA166272123	Annotation of EMA Label for zanubrutinib and MYD88	EMA							Cancer Genome		zanubrutinib	MYD88		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166273081		PA166273081	Annotation of HCSC Label for zanubrutinib and MYD88	HCSC							Cancer Genome		zanubrutinib	MYD88		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166277881		PA166277881	"Annotation of FDA Label for ravulizumab and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	FDA	On FDA Biomarker List								ravulizumab	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166182758		PA166182758	"Annotation of FDA Label for goserelin and ESR1, ESR2, PGR"	FDA	On FDA Biomarker List						Cancer Genome		goserelin	ESR1; ESR2; PGR		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166272141		PA166272141	Annotation of EMA Label for voxelotor and HBB	EMA									voxelotor	HBB		12/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166278621		PA166278621	Annotation of HCSC Label for satralizumab and AQP4	HCSC									satralizumab	AQP4		9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166274001		PA166274001	"Annotation of EMA Label for blinatumomab and ABL1, BCR, CD19"	EMA							Cancer Genome		blinatumomab	ABL1; BCR; CD19		5/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166316281		PA166316281	Annotation of FDA Label for trofinetide and MECP2	FDA	On FDA Biomarker List								trofinetide	MECP2		
https://www.pharmgkb.org/labelAnnotation/PA166316301		PA166316301	Annotation of FDA Label for plazomicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	plazomicin	MT-RNR1	rs267606617	
https://www.pharmgkb.org/labelAnnotation/PA166316321		PA166316321	Annotation of FDA Label for amikacin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	amikacin	MT-RNR1	rs267606617	
https://www.pharmgkb.org/labelAnnotation/PA166316341		PA166316341	Annotation of FDA Label for tobramycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	tobramycin	MT-RNR1	rs267606617	
https://www.pharmgkb.org/labelAnnotation/PA166317541		PA166317541	Annotation of EMA Label for ganaxolone and CDKL5	EMA		Testing Required							ganaxolone	CDKL5		
https://www.pharmgkb.org/labelAnnotation/PA166317601		PA166317601	Annotation of EMA Label for futibatinib and FGFR2	EMA		Testing Required					Cancer Genome		futibatinib	FGFR2	rs1057519045; rs1057519797	10/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166317742		PA166317742	Annotation of EMA Label for margetuximab	EMA									margetuximab			
https://www.pharmgkb.org/labelAnnotation/PA166184524		PA166184524	"Annotation of FDA Label for alpelisib and ERBB2, ESR1, ESR2, PIK3CA"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		alpelisib	ERBB2; ESR1; ESR2; PIK3CA		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166190261		PA166190261	"Annotation of FDA Label for estradiol / progesterone and PROC, PROS1, SERPINC1"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	estradiol / progesterone	PROC; PROS1; SERPINC1		
https://www.pharmgkb.org/labelAnnotation/PA166251561		PA166251561	Annotation of FDA Label for casimersen and DMD	FDA	On FDA Biomarker List	Testing Required							casimersen	DMD		8/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166251621		PA166251621	Annotation of FDA Label for viloxazine and SLCO1B1	FDA	On FDA Biomarker List								viloxazine	SLCO1B1		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166182721		PA166182721	"Annotation of FDA Label for erdafitinib and FGFR2, FGFR3"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		erdafitinib	FGFR2; FGFR3		8/31/2023
https://www.pharmgkb.org/labelAnnotation/PA166159964		PA166159964	"Annotation of FDA Label for olaparib and BRCA1, BRCA2, ERBB2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		9/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166251522		PA166251522	Annotation of FDA Label for cabotegravir / rilpivirine and HLA-B	FDA	On FDA Biomarker List								cabotegravir / rilpivirine	HLA-B		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166268882		PA166268882	"Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	belzutifan	CYP2C19; UGT2B17	CYP2C19*2; CYP2C19*3	9/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166182722		PA166182722	Annotation of FDA Label for erdafitinib and CYP2C9	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	erdafitinib	CYP2C9	CYP2C9*3	10/9/2019
https://www.pharmgkb.org/labelAnnotation/PA166316381		PA166316381	Annotation of FDA Label for gentamicin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	gentamicin	MT-RNR1	rs267606617	
https://www.pharmgkb.org/labelAnnotation/PA166316361		PA166316361	Annotation of FDA Label for streptomycin and MT-RNR1	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	streptomycin	MT-RNR1	rs267606617	
https://www.pharmgkb.org/labelAnnotation/PA166317641		PA166317641	Annotation of EMA Label for mavacamten and CYP2C19	EMA		Testing Required	Prescribing Info	Dosing Info				Prescribing	mavacamten	CYP2C19	CYP2C19*1; CYP2C19*2; CYP2C19*3	7/24/2024
https://www.pharmgkb.org/labelAnnotation/PA166313401		PA166313401	Annotation of FDA Label for lecanemab and APOE	FDA	On FDA Biomarker List	Testing Required							lecanemab	APOE	rs429358; rs7412	8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166317521		PA166317521	"Annotation of EMA Label for asciminib and ABL1, BCR"	EMA		Testing Required					Cancer Genome		asciminib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166251601		PA166251601	Annotation of FDA Label for viloxazine and CYP2D6	FDA	On FDA Biomarker List	Informative PGx							viloxazine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166184754		PA166184754	Annotation of FDA Label for procainamide and NAT2	FDA	On FDA Biomarker List	Informative PGx							procainamide	NAT2		9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166235901		PA166235901	"Annotation of FDA Label for margetuximab and FCGR2A, FCGR2B, FCGR3A"	FDA	On FDA Biomarker List	No Clinical PGx							margetuximab	FCGR2A; FCGR2B; FCGR3A		
https://www.pharmgkb.org/labelAnnotation/PA166317442		PA166317442	"Annotation of EMA Label for Ascorbic acid (vitamin C), plain"	EMA									"Ascorbic acid (vitamin C), plain"			
https://www.pharmgkb.org/labelAnnotation/PA166317443		PA166317443	Annotation of EMA Label for desmopressin	EMA									desmopressin			
https://www.pharmgkb.org/labelAnnotation/PA166317444		PA166317444	Annotation of EMA Label for levothyroxine	EMA									levothyroxine			
https://www.pharmgkb.org/labelAnnotation/PA166317445		PA166317445	Annotation of EMA Label for olutasidenib	EMA									olutasidenib			
https://www.pharmgkb.org/labelAnnotation/PA166317461		PA166317461	Annotation of EMA Label for mirvetuximab soravtansine	EMA									mirvetuximab soravtansine			
https://www.pharmgkb.org/labelAnnotation/PA166317441		PA166317441	Annotation of EMA Label for adagrasib	EMA									adagrasib			
https://www.pharmgkb.org/labelAnnotation/PA166317481		PA166317481	Annotation of EMA Label for desflurane	EMA									desflurane			
https://www.pharmgkb.org/labelAnnotation/PA166317482		PA166317482	Annotation of EMA Label for isoflurane	EMA									isoflurane			
https://www.pharmgkb.org/labelAnnotation/PA166317483		PA166317483	Annotation of EMA Label for belzutifan	EMA									belzutifan			
https://www.pharmgkb.org/labelAnnotation/PA166317501		PA166317501	Annotation of EMA Label for sevoflurane	EMA									sevoflurane			
https://www.pharmgkb.org/labelAnnotation/PA166317502		PA166317502	Annotation of EMA Label for succinylcholine	EMA									succinylcholine			
https://www.pharmgkb.org/labelAnnotation/PA166317503		PA166317503	Annotation of EMA Label for escitalopram	EMA									escitalopram			
https://www.pharmgkb.org/labelAnnotation/PA166317504		PA166317504	Annotation of EMA Label for estradiol valerate	EMA									estradiol valerate			
https://www.pharmgkb.org/labelAnnotation/PA166317581		PA166317581	Annotation of EMA Label for capmatinib and MET	EMA		Testing Required					Cancer Genome		capmatinib	MET		
https://www.pharmgkb.org/labelAnnotation/PA166317741		PA166317741	Annotation of EMA Label for infigratinib	EMA									infigratinib			
https://www.pharmgkb.org/labelAnnotation/PA166317721		PA166317721	Annotation of EMA Label for casimersen	EMA									casimersen			
https://www.pharmgkb.org/labelAnnotation/PA166317701		PA166317701	Annotation of EMA Label for golodirsen	EMA									golodirsen			
https://www.pharmgkb.org/labelAnnotation/PA166317663		PA166317663	Annotation of EMA Label for fosphenytoin	EMA									fosphenytoin			
https://www.pharmgkb.org/labelAnnotation/PA166317662		PA166317662	Annotation of EMA Label for enflurane	EMA									enflurane			
https://www.pharmgkb.org/labelAnnotation/PA166317761		PA166317761	Annotation of EMA Label for metoclopramide	EMA									metoclopramide			
https://www.pharmgkb.org/labelAnnotation/PA166317762		PA166317762	Annotation of EMA Label for mivacurium	EMA									mivacurium			
https://www.pharmgkb.org/labelAnnotation/PA166317781		PA166317781	Annotation of EMA Label for mobocertinib	EMA									mobocertinib			
https://www.pharmgkb.org/labelAnnotation/PA166317782		PA166317782	Annotation of EMA Label for oliceridine	EMA									oliceridine			
https://www.pharmgkb.org/labelAnnotation/PA166317783		PA166317783	Annotation of EMA Label for oxymetazoline and tetracaine	EMA									oxymetazoline and tetracaine			
https://www.pharmgkb.org/labelAnnotation/PA166317681		PA166317681	Annotation of EMA Label for mitapivat and PKLR	EMA									mitapivat	PKLR	rs118204085	8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166317784		PA166317784	Annotation of EMA Label for phenytoin	EMA									phenytoin			
https://www.pharmgkb.org/labelAnnotation/PA166317801		PA166317801	Annotation of EMA Label for procainamide	EMA									procainamide			
https://www.pharmgkb.org/labelAnnotation/PA166317821		PA166317821	Annotation of EMA Label for tretinoin	EMA									tretinoin			
https://www.pharmgkb.org/labelAnnotation/PA166317841		PA166317841	Annotation of EMA Label for valproic acid	EMA									valproic acid			
https://www.pharmgkb.org/labelAnnotation/PA166317822		PA166317822	Annotation of EMA Label for viloxazine	EMA									viloxazine			
https://www.pharmgkb.org/labelAnnotation/PA166317842		PA166317842	Annotation of EMA Label for viltolarsen	EMA									viltolarsen			
https://www.pharmgkb.org/labelAnnotation/PA166317901		PA166317901	Annotation of HCSC Label for adagrasib	HCSC									adagrasib			
https://www.pharmgkb.org/labelAnnotation/PA166317902		PA166317902	"Annotation of HCSC Label for Ascorbic acid (vitamin C), plain"	HCSC									"Ascorbic acid (vitamin C), plain"			
https://www.pharmgkb.org/labelAnnotation/PA166317882		PA166317882	Annotation of HCSC Label for futibatinib	HCSC									futibatinib			
https://www.pharmgkb.org/labelAnnotation/PA166317903		PA166317903	Annotation of HCSC Label for mirvetuximab soravtansine	HCSC									mirvetuximab soravtansine			
https://www.pharmgkb.org/labelAnnotation/PA166317904		PA166317904	Annotation of HCSC Label for olutasidenib	HCSC									olutasidenib			
https://www.pharmgkb.org/labelAnnotation/PA166317905		PA166317905	Annotation of HCSC Label for pegloticase	HCSC									pegloticase			
https://www.pharmgkb.org/labelAnnotation/PA166317906		PA166317906	Annotation of HCSC Label for ganaxolone	HCSC									ganaxolone			
https://www.pharmgkb.org/labelAnnotation/PA166317883		PA166317883	Annotation of HCSC Label for mitapivat	HCSC									mitapivat			
https://www.pharmgkb.org/labelAnnotation/PA166317907		PA166317907	Annotation of HCSC Label for vutrisiran	HCSC									vutrisiran			
https://www.pharmgkb.org/labelAnnotation/PA166317884		PA166317884	Annotation of HCSC Label for casimersen	HCSC									casimersen			
https://www.pharmgkb.org/labelAnnotation/PA166317908		PA166317908	Annotation of HCSC Label for crizanlizumab-tmca	HCSC									crizanlizumab-tmca			
https://www.pharmgkb.org/labelAnnotation/PA166317941		PA166317941	Annotation of HCSC Label for lonafarnib	HCSC									lonafarnib			
https://www.pharmgkb.org/labelAnnotation/PA166317942		PA166317942	Annotation of HCSC Label for margetuximab	HCSC									margetuximab			
https://www.pharmgkb.org/labelAnnotation/PA166317961		PA166317961	Annotation of HCSC Label for mobocertinib	HCSC									mobocertinib			
https://www.pharmgkb.org/labelAnnotation/PA166317947		PA166317947	Annotation of HCSC Label for procainamide	HCSC									procainamide			
https://www.pharmgkb.org/labelAnnotation/PA166317962		PA166317962	Annotation of HCSC Label for ropeginterferon alfa-2b	HCSC									ropeginterferon alfa-2b			
https://www.pharmgkb.org/labelAnnotation/PA166317963		PA166317963	Annotation of HCSC Label for rucaparib	HCSC									rucaparib			
https://www.pharmgkb.org/labelAnnotation/PA166317949		PA166317949	Annotation of HCSC Label for viloxazine	HCSC									viloxazine			
https://www.pharmgkb.org/labelAnnotation/PA166317964		PA166317964	Annotation of HCSC Label for viltolarsen	HCSC									viltolarsen			
https://www.pharmgkb.org/labelAnnotation/PA166317950		PA166317950	Annotation of HCSC Label for voxelotor	HCSC									voxelotor			
https://www.pharmgkb.org/labelAnnotation/PA166318001		PA166318001	"Annotation of HCSC Label for setmelanotide and LEPR, PCSK1, POMC"	HCSC		Testing Required							setmelanotide	LEPR; PCSK1; POMC		
https://www.pharmgkb.org/labelAnnotation/PA166319021		PA166319021	"Annotation of FDA Label for mepolizumab and FIP1L1, PDGFRA"	FDA	On FDA Biomarker List								mepolizumab	FIP1L1; PDGFRA		
https://www.pharmgkb.org/labelAnnotation/PA166294083		PA166294083	Annotation of HCSC Label for durvalumab and CD274	HCSC							Cancer Genome		durvalumab	CD274		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166317221		PA166317221	"Annotation of FDA Label for rozanolixizumab and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE, MUSK"	FDA	On FDA Biomarker List								rozanolixizumab	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE; MUSK		
https://www.pharmgkb.org/labelAnnotation/PA166317281		PA166317281	"Annotation of FDA Label for leniolisib and PIK3CD, PIK3R1"	FDA	On FDA Biomarker List								leniolisib	PIK3CD; PIK3R1		
https://www.pharmgkb.org/labelAnnotation/PA166319001		PA166319001	"Annotation of FDA Label for sacituzumab govitecan and BRCA1, BRCA2"	FDA	On FDA Biomarker List								sacituzumab govitecan	BRCA1; BRCA2		
https://www.pharmgkb.org/labelAnnotation/PA166319101		PA166319101	Annotation of FDA Label for tofersen and SOD1	FDA	On FDA Biomarker List								tofersen	SOD1		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166317881		PA166317881	"Annotation of EMA Label for lonafarnib and LMNA, ZMPSTE24"	EMA		Testing Required							lonafarnib	LMNA; ZMPSTE24		11/21/2023
https://www.pharmgkb.org/labelAnnotation/PA166293282		PA166293282	"Annotation of FDA Label for Ascorbic acid (vitamin C), combinations, Ascorbic acid (vitamin C), plain, sodium ascorbate and G6PD"	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info	Dosing Info		Other Prescribing Guidance		Prescribing	"Ascorbic acid (vitamin C), combinations; Ascorbic acid (vitamin C), plain; sodium ascorbate"	G6PD		5/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166317948		PA166317948	Annotation of HCSC Label for rimegepant and CYP2C9	HCSC		No Clinical PGx							rimegepant	CYP2C9	CYP2C9*2; CYP2C9*3	3/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166317943		PA166317943	"Annotation of HCSC Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2"	HCSC		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166318021		PA166318021	Annotation of HCSC Label for tremelimumab	HCSC									tremelimumab			
https://www.pharmgkb.org/labelAnnotation/PA166317981		PA166317981	Annotation of HCSC Label for mavacamten and CYP2C19	HCSC		Informative PGx							mavacamten	CYP2C19		12/20/2023
https://www.pharmgkb.org/labelAnnotation/PA166318981		PA166318981	"Annotation of FDA Label for sacituzumab govitecan and ERBB2, ESR1, ESR2"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		sacituzumab govitecan	ERBB2; ESR1; ESR2		
https://www.pharmgkb.org/labelAnnotation/PA166284042		PA166284042	"Annotation of EMA Label for entrectinib and NTRK1, NTRK2, NTRK3, ROS1"	EMA		Testing Required					Cancer Genome		entrectinib	NTRK1; NTRK2; NTRK3; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166283922		PA166283922	Annotation of EMA Label for gemtuzumab ozogamicin and CD33	EMA		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166294381		PA166294381	Annotation of EMA Label for evolocumab	EMA									evolocumab			8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166184454		PA166184454	Annotation of Swissmedic Label for galantamine and CYP2D6	Swissmedic		Informative PGx							galantamine	CYP2D6		11/13/2023
https://www.pharmgkb.org/labelAnnotation/PA166283781		PA166283781	"Annotation of EMA Label for givosiran and CPOX, HMBS, PPOX"	EMA									givosiran	CPOX; HMBS; PPOX		11/20/2023
https://www.pharmgkb.org/labelAnnotation/PA166122907		PA166122907	Annotation of EMA Label for vandetanib and RET	EMA		Testing Required							vandetanib	RET		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166121250		PA166121250	"Annotation of EMA Label for lomitapide and APOB, LDLR, PCSK9"	EMA		Testing Required							lomitapide	APOB; LDLR; PCSK9		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166121252		PA166121252	Annotation of EMA Label for ofatumumab and MS4A1	EMA							Cancer Genome		ofatumumab	MS4A1		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166122968		PA166122968	Annotation of EMA Label for sildenafil	EMA									sildenafil			8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166123388		PA166123388	Annotation of EMA Label for ruxolitinib and CYP3A4	EMA									ruxolitinib	CYP3A4		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166123411		PA166123411	Annotation of EMA Label for sirolimus and CYP3A4	EMA									sirolimus	CYP3A4		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166123413		PA166123413	Annotation of EMA Label for zonisamide and CYP3A4	EMA									zonisamide	CYP3A4		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166123417		PA166123417	Annotation of EMA Label for telithromycin and CYP3A4	EMA									telithromycin	CYP3A4		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166123420		PA166123420	Annotation of EMA Label for fosamprenavir and CYP3A4	EMA									fosamprenavir	CYP3A4		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166123424		PA166123424	Annotation of EMA Label for darunavir and CYP3A4	EMA									darunavir	CYP3A4		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166317885		PA166317885	Annotation of HCSC Label for fosdenopterin	HCSC									fosdenopterin			
https://www.pharmgkb.org/labelAnnotation/PA166317945		PA166317945	Annotation of HCSC Label for oliceridine	HCSC									oliceridine			
https://www.pharmgkb.org/labelAnnotation/PA166317921		PA166317921	Annotation of HCSC Label for golodirsen	HCSC									golodirsen			
https://www.pharmgkb.org/labelAnnotation/PA166317946		PA166317946	Annotation of HCSC Label for oxymetazoline and tetracaine	HCSC									oxymetazoline and tetracaine			
https://www.pharmgkb.org/labelAnnotation/PA166104882		PA166104882	Annotation of EMA Label for desloratadine	EMA									desloratadine			9/6/2023
https://www.pharmgkb.org/labelAnnotation/PA166105315		PA166105315	Annotation of EMA Label for nelfinavir and CYP3A4	EMA									nelfinavir	CYP3A4		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166123529		PA166123529	Annotation of PMDA Label for atorvastatin and LDLR	PMDA									atorvastatin	LDLR		9/25/2023
https://www.pharmgkb.org/labelAnnotation/PA166123545		PA166123545	Annotation of PMDA Label for lenalidomide	PMDA							Cancer Genome		lenalidomide			9/26/2023
https://www.pharmgkb.org/labelAnnotation/PA166123549		PA166123549	Annotation of PMDA Label for tolterodine and CYP2D6	PMDA		Informative PGx							tolterodine	CYP2D6		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166123553		PA166123553	Annotation of PMDA Label for abacavir and HLA-B	PMDA		Informative PGx							abacavir	HLA-B		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166120286		PA166120286	Annotation of EMA Label for esomeprazole and CYP2C19	EMA		No Clinical PGx							esomeprazole	CYP2C19		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166317944		PA166317944	Annotation of HCSC Label for odevixibat and ABCB11	HCSC									odevixibat	ABCB11		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166127640		PA166127640	Annotation of HCSC Label for boceprevir and IFNL3	HCSC		No Clinical PGx							boceprevir	IFNL3		7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166119827		PA166119827	Annotation of EMA Label for dextromethorphan / quinidine and CYP2D6	EMA		No Clinical PGx							dextromethorphan / quinidine	CYP2D6		8/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166123414		PA166123414	"Annotation of EMA Label for dronedarone and CYP2D6, CYP3A4"	EMA		No Clinical PGx							dronedarone	CYP2D6; CYP3A4		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166123387		PA166123387	"Annotation of EMA Label for axitinib and CYP2C19, UGT1A1"	EMA		No Clinical PGx							axitinib	CYP2C19; UGT1A1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166127691		PA166127691	Annotation of HCSC Label for metoprolol and CYP2D6	HCSC		Informative PGx							metoprolol	CYP2D6		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166127713		PA166127713	"Annotation of HCSC Label for succinylcholine and BCHE, CACNA1S, RYR1"	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	succinylcholine	BCHE; CACNA1S; RYR1		4/1/2023
https://www.pharmgkb.org/labelAnnotation/PA166160720		PA166160720	Annotation of PMDA Label for omeprazole and CYP2C19	PMDA		Informative PGx							omeprazole	CYP2C19		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166161087		PA166161087	Annotation of PMDA Label for isoniazid and NAT2	PMDA		Informative PGx							isoniazid	NAT2		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166183789		PA166183789	Annotation of Swissmedic Label for metabutethamine and G6PD	Swissmedic		Actionable PGx	Prescribing Info					Prescribing	metabutethamine	G6PD		2/28/2023
https://www.pharmgkb.org/labelAnnotation/PA166184129		PA166184129	Annotation of Swissmedic Label for daclatasvir and IFNL3	Swissmedic		Informative PGx							daclatasvir	IFNL3		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166184380		PA166184380	"Annotation of Swissmedic Label for brivaracetam and CYP2C19, CYP2C9"	Swissmedic		Informative PGx							brivaracetam	CYP2C19; CYP2C9		
https://www.pharmgkb.org/labelAnnotation/PA166272161		PA166272161	"Annotation of EMA Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53"	EMA							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166272181		PA166272181	Annotation of EMA Label for upadacitinib and CYP2D6	EMA									upadacitinib	CYP2D6		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166272261		PA166272261	"Annotation of HCSC Label for venetoclax and FLT3, IDH1, IDH2, NPM1, TP53"	HCSC							Cancer Genome		venetoclax	FLT3; IDH1; IDH2; NPM1; TP53		8/29/2023
https://www.pharmgkb.org/labelAnnotation/PA166272621		PA166272621	Annotation of EMA Label for tafamidis and TTR	EMA									tafamidis	TTR		8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166272681		PA166272681	"Annotation of EMA Label for tipiracil / trifluridine and ERBB2, KRAS"	EMA							Cancer Genome		tipiracil / trifluridine	ERBB2; KRAS		8/27/2023
https://www.pharmgkb.org/labelAnnotation/PA166272741		PA166272741	Annotation of EMA Label for ropeginterferon alfa-2b and JAK2	EMA							Cancer Genome		ropeginterferon alfa-2b	JAK2	rs77375493	8/24/2023
https://www.pharmgkb.org/labelAnnotation/PA166273262		PA166273262	Annotation of EMA Label for ospemifene and CYP2B6	EMA									ospemifene	CYP2B6		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166278461		PA166278461	"Annotation of EMA Label for crizanlizumab-tmca and HBB, SELP"	EMA									crizanlizumab-tmca	HBB; SELP		9/26/2023
https://www.pharmgkb.org/labelAnnotation/PA166278501		PA166278501	Annotation of EMA Label for duvelisib	EMA							Cancer Genome		duvelisib			8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166281781		PA166281781	"Annotation of HCSC Label for ospemifene and CYP2B6, CYP2C9"	HCSC									ospemifene	CYP2B6; CYP2C9		8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166282861		PA166282861	Annotation of HCSC Label for nusinersen and SMN2	HCSC									nusinersen	SMN2		8/17/2023
https://www.pharmgkb.org/labelAnnotation/PA166283181		PA166283181	Annotation of HCSC Label for meloxicam and CYP2C9	HCSC									meloxicam	CYP2C9		8/15/2023
https://www.pharmgkb.org/labelAnnotation/PA166283261		PA166283261	Annotation of HCSC Label for isatuximab	HCSC							Cancer Genome		isatuximab			8/18/2023
https://www.pharmgkb.org/labelAnnotation/PA166284741		PA166284741	Annotation of HCSC Label for nivolumab and BRAF	HCSC							Cancer Genome		nivolumab	BRAF	rs113488022	9/7/2023
https://www.pharmgkb.org/labelAnnotation/PA166277721		PA166277721	Annotation of HCSC Label for anifrolumab and IFNAR1	HCSC									anifrolumab	IFNAR1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166283001		PA166283001	Annotation of EMA Label for elexacaftor / tezacaftor / ivacaftor and CFTR	EMA		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166283021		PA166283021	Annotation of HCSC Label for elexacaftor / tezacaftor / ivacaftor and CFTR	HCSC		Testing Required							elexacaftor / tezacaftor / ivacaftor	CFTR	rs113993960	4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166284661		PA166284661	Annotation of HCSC Label for pembrolizumab and BRAF	HCSC							Cancer Genome		pembrolizumab	BRAF	rs113488022	8/23/2023
https://www.pharmgkb.org/labelAnnotation/PA166284701		PA166284701	Annotation of HCSC Label for regorafenib and KRAS	HCSC							Cancer Genome		regorafenib	KRAS		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166272981		PA166272981	"Annotation of EMA Label for abrocitinib and CYP2C19, CYP2C9"	EMA		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		8/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166273001		PA166273001	"Annotation of HCSC Label for abrocitinib and CYP2C19, CYP2C9"	HCSC		No Clinical PGx							abrocitinib	CYP2C19; CYP2C9		8/11/2023
https://www.pharmgkb.org/labelAnnotation/PA166273321		PA166273321	"Annotation of EMA Label for niraparib and BRCA1, BRCA2"	EMA		Informative PGx					Cancer Genome		niraparib	BRCA1; BRCA2		9/8/2023
https://www.pharmgkb.org/labelAnnotation/PA166183424		PA166183424	"Annotation of EMA Label for rucaparib and CYP1A2, CYP2D6"	EMA		No Clinical PGx							rucaparib	CYP1A2; CYP2D6		12/5/2023
https://www.pharmgkb.org/labelAnnotation/PA166328921		PA166328921	"Annotation of FDA Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN"	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN		
https://www.pharmgkb.org/labelAnnotation/PA166328961		PA166328961	"Annotation of HCSC Label for capivasertib and AKT1, ERBB2, ESR1, ESR2, PIK3CA, PTEN"	HCSC		Testing Required					Cancer Genome		capivasertib	AKT1; ERBB2; ESR1; ESR2; PIK3CA; PTEN		
https://www.pharmgkb.org/labelAnnotation/PA166328941		PA166328941	Annotation of EMA Label for capivasertib	EMA									capivasertib			
https://www.pharmgkb.org/labelAnnotation/PA166329001		PA166329001	Annotation of EMA Label for eflornithine	EMA									eflornithine			
https://www.pharmgkb.org/labelAnnotation/PA166329021		PA166329021	Annotation of HCSC Label for eflornithine	HCSC									eflornithine			
https://www.pharmgkb.org/labelAnnotation/PA166329061		PA166329061	Annotation of EMA Label for elranatamab	EMA									elranatamab			
https://www.pharmgkb.org/labelAnnotation/PA166329043		PA166329043	Annotation of HCSC Label for elranatamab	HCSC							Cancer Genome		elranatamab			
https://www.pharmgkb.org/labelAnnotation/PA166329041		PA166329041	Annotation of FDA Label for elranatamab	FDA	On FDA Biomarker List						Cancer Genome		elranatamab			
https://www.pharmgkb.org/labelAnnotation/PA166329101		PA166329101	Annotation of FDA Label for eplontersen and TTR	FDA	On FDA Biomarker List	Testing Required							eplontersen	TTR	rs28933979	
https://www.pharmgkb.org/labelAnnotation/PA166329121		PA166329121	Annotation of EMA Label for eplontersen and TTR	EMA									eplontersen	TTR		
https://www.pharmgkb.org/labelAnnotation/PA166329141		PA166329141	Annotation of HCSC Label for quizartinib	HCSC									quizartinib			
https://www.pharmgkb.org/labelAnnotation/PA166329221		PA166329221	Annotation of FDA Label for quizartinib and FLT3	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		quizartinib	FLT3		
https://www.pharmgkb.org/labelAnnotation/PA166329241		PA166329241	Annotation of EMA Label for quizartinib and FLT3	EMA		Testing Required					Cancer Genome		quizartinib	FLT3		
https://www.pharmgkb.org/labelAnnotation/PA166329281		PA166329281	Annotation of EMA Label for repotrectinib	EMA									repotrectinib			
https://www.pharmgkb.org/labelAnnotation/PA166329301		PA166329301	Annotation of HCSC Label for repotrectinib	HCSC									repotrectinib			
https://www.pharmgkb.org/labelAnnotation/PA166329322		PA166329322	Annotation of FDA Label for repotrectinib and ROS1	FDA	On FDA Biomarker List	Testing Required					Cancer Genome		repotrectinib	ROS1		
https://www.pharmgkb.org/labelAnnotation/PA166329341		PA166329341	"Annotation of FDA Label for pirtobrutinib and BTK, IGH, TP53"	FDA	On FDA Biomarker List						Cancer Genome		pirtobrutinib	BTK; IGH; TP53		
https://www.pharmgkb.org/labelAnnotation/PA166329122		PA166329122	Annotation of HCSC Label for eplontersen and TTR	HCSC									eplontersen	TTR		7/5/2024
https://www.pharmgkb.org/labelAnnotation/PA166329401		PA166329401	Annotation of HCSC Label for zilucoplan	HCSC									zilucoplan			
https://www.pharmgkb.org/labelAnnotation/PA166329441		PA166329441	Annotation of EMA Label for pirtobrutinib and BTK	EMA							Cancer Genome		pirtobrutinib	BTK		
https://www.pharmgkb.org/labelAnnotation/PA166329525		PA166329525	Annotation of FDA Label for fruquintinib and KRAS	FDA	On FDA Biomarker List						Cancer Genome		fruquintinib	KRAS		
https://www.pharmgkb.org/labelAnnotation/PA166329481		PA166329481	Annotation of EMA Label for fruquintinib	EMA									fruquintinib			
https://www.pharmgkb.org/labelAnnotation/PA166329501		PA166329501	Annotation of HCSC Label for fruquintinib	HCSC									fruquintinib			
https://www.pharmgkb.org/labelAnnotation/PA166328981		PA166328981	Annotation of FDA Label for eflornithine and MYCN	FDA	On FDA Biomarker List	No Clinical PGx					Cancer Genome		eflornithine	MYCN		
https://www.pharmgkb.org/labelAnnotation/PA166329782		PA166329782	"Annotation of EMA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	EMA									zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
https://www.pharmgkb.org/labelAnnotation/PA166329781		PA166329781	"Annotation of FDA Label for zilucoplan and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	FDA	On FDA Biomarker List								zilucoplan	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
https://www.pharmgkb.org/labelAnnotation/PA166330041		PA166330041	Annotation of EMA Label for nedosiran and AGXT	EMA									nedosiran	AGXT		
https://www.pharmgkb.org/labelAnnotation/PA166330042		PA166330042	Annotation of HCSC Label for nedosiran and AGXT	HCSC									nedosiran	AGXT		
https://www.pharmgkb.org/labelAnnotation/PA166330081		PA166330081	"Annotation of EMA Label for nirogacestat and APC, CTNNB1"	EMA									nirogacestat	APC; CTNNB1		
https://www.pharmgkb.org/labelAnnotation/PA166330082		PA166330082	"Annotation of HCSC Label for nirogacestat and APC, CTNNB1"	HCSC									nirogacestat	APC; CTNNB1		
https://www.pharmgkb.org/labelAnnotation/PA166330101		PA166330101	"Annotation of FDA Label for nirogacestat and APC, CTNNB1"	FDA	On FDA Biomarker List								nirogacestat	APC; CTNNB1		
https://www.pharmgkb.org/labelAnnotation/PA166278001		PA166278001	"Annotation of HCSC Label for belzutifan and CYP2C19, UGT2B17"	HCSC		Informative PGx							belzutifan	CYP2C19; UGT2B17		
https://www.pharmgkb.org/labelAnnotation/PA166277701		PA166277701	Annotation of EMA Label for anifrolumab and IFNAR1	EMA									anifrolumab	IFNAR1		8/14/2023
https://www.pharmgkb.org/labelAnnotation/PA166278581		PA166278581	Annotation of HCSC Label for siponimod and CYP2C9	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	siponimod	CYP2C9	CYP2C9*1; CYP2C9*2; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166329261		PA166329261	Annotation of EMA Label for etrasimod and CYP2C9	EMA		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	etrasimod	CYP2C9		7/25/2024
https://www.pharmgkb.org/labelAnnotation/PA166329181		PA166329181	Annotation of HCSC Label for etrasimod and CYP2C9	HCSC		Informative PGx							etrasimod	CYP2C9		8/28/2024
https://www.pharmgkb.org/labelAnnotation/PA166277981		PA166277981	Annotation of HCSC Label for belzutifan and VHL	HCSC									belzutifan	VHL		8/2/2024
https://www.pharmgkb.org/labelAnnotation/PA166330061		PA166330061	Annotation of FDA Label for nedosiran and AGXT	FDA	On FDA Biomarker List								nedosiran	AGXT		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166277801		PA166277801	Annotation of HCSC Label for tebentafusp and HLA-A	HCSC		Testing Required							tebentafusp	HLA-A	HLA-A*02:01	8/14/2024
https://www.pharmgkb.org/labelAnnotation/PA166269742		PA166269742	Annotation of EMA Label for odevixibat and ABCB11	EMA									odevixibat	ABCB11		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166329161		PA166329161	Annotation of FDA Label for etrasimod and CYP2C9	FDA		Informative PGx							etrasimod	CYP2C9	CYP2C9*2; CYP2C9*3	7/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166286181		PA166286181	Annotation of HCSC Label for alectinib and ALK	HCSC		Testing Required					Cancer Genome		alectinib	ALK		4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166230001		PA166230001	Annotation of EMA Label for avapritinib and PDGFRA	EMA		Testing Required					Cancer Genome		avapritinib	PDGFRA	rs121908585	4/15/2024
https://www.pharmgkb.org/labelAnnotation/PA166278421		PA166278421	"Annotation of EMA Label for cemiplimab-rwlc and ALK, CD274, EGFR, ROS1"	EMA		Testing Required					Cancer Genome		cemiplimab-rwlc	ALK; CD274; EGFR; ROS1		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166284542		PA166284542	Annotation of HCSC Label for encorafenib and BRAF	HCSC		Testing Required					Cancer Genome		encorafenib	BRAF	rs113488022	4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166284282		PA166284282	Annotation of HCSC Label for gemtuzumab ozogamicin and CD33	HCSC		Testing Required					Cancer Genome		gemtuzumab ozogamicin	CD33		4/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166334981		PA166334981	Annotation of EMA Label for fluorouracil	EMA									fluorouracil			
https://www.pharmgkb.org/labelAnnotation/PA166283841		PA166283841	Annotation of HCSC Label for infigratinib and FGFR2	HCSC		Testing Required					Cancer Genome		infigratinib	FGFR2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166182954		PA166182954	Annotation of EMA Label for ivacaftor / tezacaftor and CFTR	EMA		Testing Required							ivacaftor / tezacaftor	CFTR	rs113993960; rs121908752; rs121908753; rs141033578; rs202179988; rs368505753; rs397508288; rs397508442; rs397508761; rs74551128; rs75039782; rs75541969; rs76151804; rs77834169; rs80224560	4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183209		PA166183209	Annotation of EMA Label for migalastat and GLA	EMA		Testing Required							migalastat	GLA		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166183243		PA166183243	"Annotation of EMA Label for olaparib and BRCA1, BRCA2, ERBB2"	EMA		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166282882		PA166282882	"Annotation of HCSC Label for olaparib and BRCA1, BRCA2, ERBB2"	HCSC		Testing Required					Cancer Genome		olaparib	BRCA1; BRCA2; ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166284121		PA166284121	Annotation of HCSC Label for trastuzumab deruxtecan and ERBB2	HCSC		Testing Required					Cancer Genome		trastuzumab deruxtecan	ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166335921		PA166335921	Annotation of HCSC Label for vincristine	HCSC									vincristine			
https://www.pharmgkb.org/labelAnnotation/PA166335941		PA166335941	Annotation of EMA Label for vincristine	EMA									vincristine			
https://www.pharmgkb.org/labelAnnotation/PA166336642		PA166336642	Annotation of HCSC Label for eliglustat and CYP2D6	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug			Prescribing	eliglustat	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166336761		PA166336761	Annotation of EMA Label for tafenoquine	EMA									tafenoquine			
https://www.pharmgkb.org/labelAnnotation/PA166335081		PA166335081	"Annotation of HCSC Label for lapatinib and HLA-DQA1, HLA-DRB1"	HCSC		Informative PGx							lapatinib	HLA-DQA1; HLA-DRB1	HLA-DQA1*02:01; HLA-DRB1*07:01	
https://www.pharmgkb.org/labelAnnotation/PA166122548		PA166122548	Annotation of EMA Label for velaglucerase alfa and GBA	EMA									velaglucerase alfa	GBA		8/6/2024
https://www.pharmgkb.org/labelAnnotation/PA166273301		PA166273301	"Annotation of EMA Label for nivolumab and ALK, CD274, EGFR, ERBB2"	EMA		Testing Required					Cancer Genome		nivolumab	ALK; CD274; EGFR; ERBB2		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166127641		PA166127641	"Annotation of HCSC Label for bosutinib and ABL1, BCR"	HCSC		Testing Required					Cancer Genome		bosutinib	ABL1; BCR		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166336762		PA166336762	Annotation of HCSC Label for tafenoquine	HCSC									tafenoquine			
https://www.pharmgkb.org/labelAnnotation/PA166336781		PA166336781	Annotation of EMA Label for afutuzumab and MS4A1	EMA							Cancer Genome		afutuzumab	MS4A1		
https://www.pharmgkb.org/labelAnnotation/PA166336801		PA166336801	Annotation of EMA Label for allopurinol	EMA									allopurinol			
https://www.pharmgkb.org/labelAnnotation/PA166337801		PA166337801	"Annotation of HCSC Label for efgartigimod alfa and CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNE"	HCSC									efgartigimod alfa	CHRNA1; CHRNA3; CHRNA4; CHRNA5; CHRNA6; CHRNA7; CHRNB1; CHRNE		
https://www.pharmgkb.org/labelAnnotation/PA166337821		PA166337821	Annotation of HCSC Label for duvelisib	HCSC									duvelisib			
https://www.pharmgkb.org/labelAnnotation/PA166337841		PA166337841	Annotation of HCSC Label for anakinra and NLRP3	HCSC									anakinra	NLRP3		
https://www.pharmgkb.org/labelAnnotation/PA166337881		PA166337881	Annotation of HCSC Label for avapritinib	HCSC									avapritinib			
https://www.pharmgkb.org/labelAnnotation/PA166337902		PA166337902	Annotation of EMA Label for avelumab and CD274	EMA									avelumab	CD274		
https://www.pharmgkb.org/labelAnnotation/PA166337901		PA166337901	Annotation of HCSC Label for avelumab and CD274	HCSC									avelumab	CD274		
https://www.pharmgkb.org/labelAnnotation/PA166337941		PA166337941	Annotation of EMA Label for amifampridine	EMA									amifampridine			
https://www.pharmgkb.org/labelAnnotation/PA166339041		PA166339041	Annotation of HCSC Label for binimetinib and BRAF	HCSC		Testing Required					Cancer Genome		binimetinib	BRAF	rs113488022	
https://www.pharmgkb.org/labelAnnotation/PA166339181		PA166339181	Annotation of HCSC Label for brigatinib and ALK	HCSC		Testing Required					Cancer Genome		brigatinib	ALK		
https://www.pharmgkb.org/labelAnnotation/PA166339221		PA166339221	Annotation of EMA Label for erdafitinib	EMA									erdafitinib			
https://www.pharmgkb.org/labelAnnotation/PA166339241		PA166339241	Annotation of HCSC Label for ibritumomab and MS4A1	HCSC							Cancer Genome		ibritumomab	MS4A1		
https://www.pharmgkb.org/labelAnnotation/PA166339262		PA166339262	Annotation of HCSC Label for cobimetinib and BRAF	HCSC		Testing Required					Cancer Genome		cobimetinib	BRAF	rs113488022	
https://www.pharmgkb.org/labelAnnotation/PA166339301		PA166339301	Annotation of HCSC Label for elacestrant	HCSC									elacestrant			
https://www.pharmgkb.org/labelAnnotation/PA166339321		PA166339321	Annotation of EMA Label for elacestrant and ESR1	EMA		Testing Required					Cancer Genome		elacestrant	ESR1		
https://www.pharmgkb.org/labelAnnotation/PA166339442		PA166339442	Annotation of EMA Label for gilteritinib and FLT3	EMA		Testing Required					Cancer Genome		gilteritinib	FLT3		
https://www.pharmgkb.org/labelAnnotation/PA166339443		PA166339443	Annotation of HCSC Label for gilteritinib and FLT3	HCSC		Testing Required					Cancer Genome		gilteritinib	FLT3		
https://www.pharmgkb.org/labelAnnotation/PA166339461		PA166339461	"Annotation of HCSC Label for larotrectinib and NTRK1, NTRK2, NTRK3"	HCSC		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		
https://www.pharmgkb.org/labelAnnotation/PA166339462		PA166339462	"Annotation of EMA Label for larotrectinib and NTRK1, NTRK2, NTRK3"	EMA		Testing Required					Cancer Genome		larotrectinib	NTRK1; NTRK2; NTRK3		
https://www.pharmgkb.org/labelAnnotation/PA166339481		PA166339481	Annotation of HCSC Label for lorlatinib and ALK	HCSC		Testing Required					Cancer Genome		lorlatinib	ALK		
https://www.pharmgkb.org/labelAnnotation/PA166337861		PA166337861	Annotation of EMA Label for anakinra and NLRP3	EMA									anakinra	NLRP3		
https://www.pharmgkb.org/labelAnnotation/PA166337961		PA166337961	Annotation of FDA Label for atazanavir and CYP2C19	FDA		Informative PGx							atazanavir	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166339061		PA166339061	Annotation of HCSC Label for binimetinib and UGT1A1	HCSC		No Clinical PGx							binimetinib	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166284642		PA166284642	"Annotation of HCSC Label for pembrolizumab and ALK, CD274, EGFR, ERBB2"	HCSC		Testing Required					Cancer Genome		pembrolizumab	ALK; CD274; EGFR; ERBB2		4/21/2024
https://www.pharmgkb.org/labelAnnotation/PA166340121		PA166340121	Annotation of EMA Label for amphetamine	EMA									amphetamine			
https://www.pharmgkb.org/labelAnnotation/PA166341882		PA166341882	Annotation of EMA Label for dostarlimab	EMA		Testing Required					Cancer Genome		dostarlimab			
https://www.pharmgkb.org/labelAnnotation/PA166336561		PA166336561	Annotation of EMA Label for teclistamab	EMA									teclistamab			
https://www.pharmgkb.org/labelAnnotation/PA166336562		PA166336562	Annotation of HCSC Label for teclistamab	HCSC									teclistamab			
https://www.pharmgkb.org/labelAnnotation/PA166341881		PA166341881	Annotation of HCSC Label for dostarlimab	HCSC		Testing Required					Cancer Genome		dostarlimab			
https://www.pharmgkb.org/labelAnnotation/PA166340141		PA166340141	Annotation of HCSC Label for amphetamine and CYP2D6	HCSC		No Clinical PGx							amphetamine	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166340161		PA166340161	"Annotation of FDA Label for axitinib and CYP2C19, UGT1A1"	FDA		No Clinical PGx							axitinib	CYP2C19; UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166340181		PA166340181	"Annotation of HCSC Label for axitinib and CYP2C19, UGT1A1"	HCSC		No Clinical PGx							axitinib	CYP2C19; UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166343901		PA166343901	"Annotation of HCSC Label for avatrombopag and CYP2C9, F2, F5, PROC, PROS1, SERPINC1"	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	avatrombopag	CYP2C9; F2; F5; PROC; PROS1; SERPINC1	CYP2C9*2; CYP2C9*3; rs1799963; rs6025	7/17/2024
https://www.pharmgkb.org/labelAnnotation/PA166344821		PA166344821	Annotation of HCSC Label for dapsone and CYB5R3	HCSC		Actionable PGx	Prescribing Info		Alternate Drug			Prescribing	dapsone	CYB5R3		
https://www.pharmgkb.org/labelAnnotation/PA166344841		PA166344841	Annotation of HCSC Label for dolutegravir and UGT1A1	HCSC		Informative PGx							dolutegravir	UGT1A1		
https://www.pharmgkb.org/labelAnnotation/PA166344641		PA166344641	Annotation of HCSC Label for azathioprine and NUDT15	HCSC		Testing Required	Prescribing Info	Dosing Info				Prescribing	azathioprine	NUDT15	rs116855232	
https://www.pharmgkb.org/labelAnnotation/PA166278381		PA166278381	"Annotation of EMA Label for bupivacaine and CYB5R3, G6PD"	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	bupivacaine	CYB5R3; G6PD		7/18/2024
https://www.pharmgkb.org/labelAnnotation/PA166344721		PA166344721	Annotation of HCSC Label for bupivacaine	HCSC									bupivacaine			
https://www.pharmgkb.org/labelAnnotation/PA166345022		PA166345022	Annotation of FDA Label for flibanserin and CYP2C19	FDA	On FDA Biomarker List	Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	flibanserin	CYP2C19		
https://www.pharmgkb.org/labelAnnotation/PA166345321		PA166345321	Annotation of HCSC Label for glyburide and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glyburide	CYP2C9	CYP2C9*2; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166345341		PA166345341	Annotation of HCSC Label for glimepiride and CYP2C9	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	glimepiride	CYP2C9	CYP2C9*2; CYP2C9*3	
https://www.pharmgkb.org/labelAnnotation/PA166122947		PA166122947	Annotation of EMA Label for ranolazine and CYP2D6	EMA		Actionable PGx	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	ranolazine	CYP2D6		7/22/2024
https://www.pharmgkb.org/labelAnnotation/PA166345301		PA166345301	"Annotation of HCSC Label for rosuvastatin and ABCG2, SLCO1B1"	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	rosuvastatin	ABCG2; SLCO1B1	rs2231142; rs4149056	
https://www.pharmgkb.org/labelAnnotation/PA166344521		PA166344521	Annotation of HCSC Label for tramadol and CYP2D6	HCSC		Informative PGx							tramadol	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166344801		PA166344801	Annotation of FDA Label for dapsone and G6PD	FDA	On FDA Biomarker List	No Clinical PGx							dapsone	G6PD		7/19/2024
https://www.pharmgkb.org/labelAnnotation/PA166273581		PA166273581	"Annotation of EMA Label for inclisiran and APOB, LDLR, PCSK9"	EMA									inclisiran	APOB; LDLR; PCSK9		7/23/2024
https://www.pharmgkb.org/labelAnnotation/PA166345781		PA166345781	Annotation of HCSC Label for metoclopramide and CYP2D6	HCSC		Actionable PGx	Prescribing Info	Dosing Info				Prescribing	metoclopramide	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166345921		PA166345921	Annotation of HCSC Label for primaquine and G6PD	HCSC		Testing Required	Prescribing Info	Dosing Info	Alternate Drug	Other Prescribing Guidance		Prescribing	primaquine	G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166346941		PA166346941	"Annotation of HCSC Label for dabrafenib and HRAS, KRAS, NRAS"	HCSC		Actionable PGx	Prescribing Info			Other Prescribing Guidance		Prescribing	dabrafenib	HRAS; KRAS; NRAS		
https://www.pharmgkb.org/labelAnnotation/PA166346641		PA166346641	Annotation of EMA Label for letrozole	EMA									letrozole			
https://www.pharmgkb.org/labelAnnotation/PA166114482		PA166114482	Annotation of EMA Label for vemurafenib and BRAF	EMA		Testing Required					Cancer Genome		vemurafenib	BRAF		8/4/2024
https://www.pharmgkb.org/labelAnnotation/PA166346802		PA166346802	Annotation of HCSC Label for azacitidine	HCSC									azacitidine			
https://www.pharmgkb.org/labelAnnotation/PA166346841		PA166346841	Annotation of HCSC Label for cerliponase alfa and TPP1	HCSC									cerliponase alfa	TPP1		
https://www.pharmgkb.org/labelAnnotation/PA166338381		PA166338381	"Annotation of EMA Label for dabrafenib and HRAS, KRAS, NRAS"	EMA		Actionable PGx	Prescribing Info			Other Prescribing Guidance	Cancer Genome	Prescribing	dabrafenib	HRAS; KRAS; NRAS		
https://www.pharmgkb.org/labelAnnotation/PA166346981		PA166346981	Annotation of EMA Label for denileukin diftitox	EMA									denileukin diftitox			
https://www.pharmgkb.org/labelAnnotation/PA166347001		PA166347001	Annotation of HCSC Label for denileukin diftitox	HCSC									denileukin diftitox			
https://www.pharmgkb.org/labelAnnotation/PA166347081		PA166347081	Annotation of HCSC Label for elosulfase alfa and GALNS	HCSC									elosulfase alfa	GALNS		
https://www.pharmgkb.org/labelAnnotation/PA166347101		PA166347101	Annotation of EMA Label for eteplirsen	EMA									eteplirsen			
https://www.pharmgkb.org/labelAnnotation/PA166347121		PA166347121	Annotation of HCSC Label for eteplirsen	HCSC									eteplirsen			
https://www.pharmgkb.org/labelAnnotation/PA166347141		PA166347141	Annotation of FDA Label for abemaciclib and MKI67	FDA	On FDA Biomarker List						Cancer Genome		abemaciclib	MKI67		
https://www.pharmgkb.org/labelAnnotation/PA166347181		PA166347181	Annotation of FDA Label for tremelimumab and CD274	FDA	On FDA Biomarker List						Cancer Genome		tremelimumab	CD274		
https://www.pharmgkb.org/labelAnnotation/PA166283881		PA166283881	"Annotation of HCSC Label for glycerol phenylbutyrate and ARG1, ASL, ASS1, CPS1, OTC"	HCSC		Testing Required							glycerol phenylbutyrate	ARG1; ASL; ASS1; CPS1; OTC		8/7/2024
https://www.pharmgkb.org/labelAnnotation/PA166272221		PA166272221	Annotation of HCSC Label for tucatinib and ERBB2	HCSC							Cancer Genome		tucatinib	ERBB2		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166272201		PA166272201	Annotation of EMA Label for tucatinib and ERBB2	EMA							Cancer Genome		tucatinib	ERBB2		8/16/2024
https://www.pharmgkb.org/labelAnnotation/PA166345821		PA166345821	"Annotation of HCSC Label for metoclopramide and CYB5R1, CYB5R2, CYB5R3, CYB5R4, G6PD"	HCSC		Informative PGx							metoclopramide	CYB5R1; CYB5R2; CYB5R3; CYB5R4; G6PD		
https://www.pharmgkb.org/labelAnnotation/PA166347161		PA166347161	Annotation of FDA Label for anakinra and NLRP3	FDA	On FDA Biomarker List								anakinra	NLRP3		8/26/2024
https://www.pharmgkb.org/labelAnnotation/PA166345861		PA166345861	Annotation of HCSC Label for mirabegron and CYP2D6	HCSC		No Clinical PGx							mirabegron	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166347361		PA166347361	Annotation of HCSC Label for gefitinib and CYP2D6	HCSC		Informative PGx							gefitinib	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166273441		PA166273441	Annotation of EMA Label for lumasiran and AGXT	EMA									lumasiran	AGXT		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166278481		PA166278481	"Annotation of HCSC Label for lutetium (177Lu) oxodotreotide and SSTR1, SSTR2, SSTR3, SSTR4, SSTR5"	HCSC		Testing Required					Cancer Genome		lutetium (177Lu) oxodotreotide	SSTR1; SSTR2; SSTR3; SSTR4; SSTR5		8/8/2024
https://www.pharmgkb.org/labelAnnotation/PA166273381		PA166273381	"Annotation of EMA Label for metreleptin and AGPAT2, BSCL2, LEP, LMNB2"	EMA		Testing Required							metreleptin	AGPAT2; BSCL2; LEP; LMNB2		8/9/2024
https://www.pharmgkb.org/labelAnnotation/PA166347601		PA166347601	Annotation of HCSC Label for midostaurin and FLT3	HCSC		Testing Required					Cancer Genome		midostaurin	FLT3		
https://www.pharmgkb.org/labelAnnotation/PA166347622		PA166347622	Annotation of HCSC Label for migalastat and GLA	HCSC		Testing Required							migalastat	GLA		
https://www.pharmgkb.org/labelAnnotation/PA166347641		PA166347641	Annotation of HCSC Label for neratinib and ERBB2	HCSC		Testing Required					Cancer Genome		neratinib	ERBB2		
https://www.pharmgkb.org/labelAnnotation/PA166347741		PA166347741	Annotation of HCSC Label for osimertinib and EGFR	HCSC		Testing Required					Cancer Genome		osimertinib	EGFR	rs121434568; rs121434569	
https://www.pharmgkb.org/labelAnnotation/PA166347901		PA166347901	Annotation of FDA Label for panitumumab and EGFR	FDA	On FDA Biomarker List								panitumumab	EGFR		
https://www.pharmgkb.org/labelAnnotation/PA166273121		PA166273121	Annotation of EMA Label for pralsetinib and RET	EMA		Testing Required					Cancer Genome		pralsetinib	RET		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166278701		PA166278701	"Annotation of HCSC Label for risdiplam and SMN1, SMN2"	HCSC		Testing Required							risdiplam	SMN1; SMN2		8/13/2024
https://www.pharmgkb.org/labelAnnotation/PA166347941		PA166347941	Annotation of HCSC Label for toremifene	HCSC									toremifene			
https://www.pharmgkb.org/labelAnnotation/PA166273241		PA166273241	Annotation of EMA Label for paliperidone and CYP2D6	EMA		No Clinical PGx							paliperidone	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166122966		PA166122966	Annotation of EMA Label for darifenacin and CYP2D6	EMA		Informative PGx							darifenacin	CYP2D6		8/7/2014
https://www.pharmgkb.org/labelAnnotation/PA166121326		PA166121326	Annotation of EMA Label for pazopanib and HLA-B	EMA		Informative PGx							pazopanib	HLA-B	HLA-B*57:01	6/5/2014
https://www.pharmgkb.org/labelAnnotation/PA166347921		PA166347921	Annotation of HCSC Label for tamoxifen and CYP2D6	HCSC		Informative PGx							tamoxifen	CYP2D6		
https://www.pharmgkb.org/labelAnnotation/PA166347961		PA166347961	Annotation of FDA Label for sulfasalazine and NAT2	FDA	On FDA Biomarker List	Informative PGx							sulfasalazine	NAT2		
https://www.pharmgkb.org/labelAnnotation/PA166347981		PA166347981	Annotation of HCSC Label for sulfasalazine and NAT2	HCSC		Informative PGx							sulfasalazine	NAT2		
